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• The diabetic microenvironment causes changes in the MicroRNA milieu 28 
• Some miRNAs demonstrate dysregulation across multiple diabetomimetic stimuli 29 
• Affected miRNAs target genes in FOXO1, HIPPO and Lysine degradation pathways 30 






Altered expression of miRNAs is evident in the islets of diabetic human donors, but the effects 35 
of specific aspects of the diabetic microenvironment and identity of gene ontology pathways 36 
demonstrating target gene enrichment in response to each is understudied.   37 
 38 
We assessed changes in the miRNA milieu in response to high/low glucose, hypoxia, 39 
dyslipidaemia and inflammatory factors in a humanised EndoC-H1 beta cell culture system 40 
and performed miRPath analysis for each treatment individually. The 10 miRNAs 41 
demonstrating the greatest dysregulation across treatments were then independently 42 
validated and Gene Set Enrichment Analysis to confirm targeted pathways undertaken.  43 
 44 
171 of 392 miRNAs displayed altered expression in response to one or more cellular stressors. 45 
miRNA changes were treatment specific, but their target genes were enriched in conserved 46 
pathways. 5 miRNAs (miR-136-5p, miR299-5p, miR-454-5p, miR-152 and miR-185) were 47 
dysregulated in response to multiple stressors and survived validation in independent samples 48 
(p=0.008, 0.002, 0.012, 0.005 and 0.024 respectively). Target genes of dysregulated miRNAs 49 
were clustered into FOXO1, HIPPO and Lysine degradation pathways (p= 0.02, p= 5.84 x 10-50 
5 and p =3.00 x 10-3 respectively).  51 
 52 
We provide evidence that the diabetic microenvironment may induce changes to the 53 
expression of miRNAs targeting genes enriched in pathways involved in cell stress response 54 




Cellular stresses are known to be associated with the pathogenesis of several common, 57 
chronic diseases, such as type 2 diabetes, cancer and neurodegenerative disorders. Stressful 58 
stimuli such as chronic hyperglycaemia, dyslipidaemia, inflammation and hypoxia contribute 59 
to insulin resistance and dysregulated insulin secretion (1-3) and are also associated with 60 
tumorigenesis, where chronic inflammation is suggested to be instrumental in loss of 61 
regulatory control over cell proliferation, migration and cell-cell interactions (4). Likewise in 62 
neurodegenerative conditions such as Alzheimer’s disease, oxidative stress is a feature of the 63 
disease process, contributing to initiation of inflammatory responses (5, 6).   64 
 65 
The biosynthesis, regulation, recruitment and interaction of microRNAs with their targets are 66 
integral to the cellular stress response (7-9). MicroRNAs (miRNA) are a class of small non-67 
coding RNAs, which regulate gene expression by mRNA degradation and/or translational 68 
repression (10-12). Previous studies have shown that various components of stress response 69 
pathways such as the DNA damage response protein p53 have been shown to regulate the 70 
biosynthesis of microRNAs following exposure to damaging stimuli (13). As part of this, stress 71 
granule formation is also associated with the regulation of miRNA synthesis along with 72 
recruitment of proteins such as Argonaute that are involved in miRNA trafficking and the RISC 73 
complex (14). MicroRNA synthesis can also be affected in response to oxidative stress, which 74 
has been shown to contribute to reduced expression of Dicer, essential for miRNA synthesis, 75 
(15) and to be linked to reduced stress tolerance in cells (15, 16). Alongside the impact of 76 
cellular stress responses on miRNA synthesis, miRNAs themselves contribute to coordination 77 
of the cellular stress response by regulating the levels of components of the unfolded protein 78 
response, such as the negative regulation of XBP1 during endoplasmic reticulum stress, which 79 
is regulated by miR-214. (17, 18). Cellular stress is also thought to dysregulate 80 
microRNA:mRNA target interactions by virtue of the system becoming overwhelmed as a 81 
result of large increases in the expression of mRNA targets (8).  82 
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The cellular microenvironment brought about by type 2 diabetes (T2D) is stressful for 83 
pancreatic beta cells. We therefore aimed to characterise changes in the beta cell miRNA 84 
repertoire in response to diabetes-related cellular stressors. We exposed the human 85 
EndoCH1 beta cell line to disrupted glycaemia, altered lipids, hypoxia or proinflammatory 86 
cytokines, and then characterised effects on the miRNA milieu in a single sample consisting 87 
of 3 pooled replicates to identify the miRNAs with the largest consistent fold changes across 88 
assays for validation. 368 miRNAs were expressed in EndoCH1 cells, of which 171 showed 89 
evidence of altered expression upon treatment with one or more diabetes-associated factors. 90 
The 10 most dysregulated miRNAs across all treatments were then validated in 3 biological 91 
and 3 technical replicates to allow assessment of statistical significance. Their targets were 92 
then predicted using bioinformatics and validated using qRTPCR. GSEA gene ontology 93 
analysis revealed that the FOXO1 and HIPPO pathways, known to be important in 94 
maintenance of beta cell fate and function (19, 20), were enriched in target genes of 95 
dysregulated miRNAs. These results suggest that the cellular microenvironment can induce 96 
changes in the expression of miRNAs in human beta cells, and that these miRNAs may target 97 
genes involved in cell survival. 98 
 99 
Research Design and Methods 100 
 101 
Culture and treatment of EndoC-βH1 cells 102 
 103 
EndoC-βH1 cells at passage <25 were plated in 24-well plates at a density of 6.0 x 105 cells/ 104 
ml and maintained according to a modified humanised culture protocol as previously described 105 
for 72 hrs prior to treatment (21). Cells were then treated with low (2.5 mM) or high glucose 106 
(25 mM) for 24, 36 or 48 hrs to mimic disrupted glycaemia, with 0.5 mM palmitic acid, 0.5 mM 107 
oleic acid or 0.5 mM palmitic acid/0.5 mM oleic acid for 12, 24 and 48 hrs to mimic 108 
dyslipidaemia, with TNF𝛼 (1000 U/ mL, INF𝛾 (750 U/ mL) and IL1𝛽 (75 U/ mL) for 12, 24 and 109 
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36 hrs to mimic inflammatory changes or were grown in 1%, 3% or 21% O2 for a period of 24, 110 
36 or 48 hrs to mimic hypoxia. We did not measure insulin secretion or other functional 111 
parameters, because the responses of this cell line are already well documented in this regard 112 
(22-24).    113 
 114 
RNA extraction and reverse transcription 115 
 116 
Treated cells were washed in Dulbecco’s phosphate buffered saline (D-PBS) before RNA 117 
extraction using TRI® reagent to harvest both the small RNA (<200bp) and mRNA/lncRNA 118 
fractions (Sigma-Aldrich, Steinheim, Germany). RNA concentrations were adjusted to 100 ng/ 119 
μL prior to reverse transcription. For miRNA assessment, cDNA synthesis was carried out in 120 
20 μL reactions using the Taqman® Advanced miRNA Assay kit (Thermo Fisher, Waltham, 121 
MA USA) according to the manufacturer’s instructions. For assessment of mRNA target levels, 122 
cDNA synthesis was carried out using EvoScript Universal cDNA master (Roche life science, 123 
Burgess Hill, UK). Samples were normalised to 100 ng/ μL RNA prior to reverse transcription. 124 
 125 
Large-scale miRNA screen 126 
 127 
The miRNA milieu of treated and endogenous control cells was assessed using Taqman® 128 
Advanced miRNA (miR) Open Arrays on the Thermo Fisher 12K OpenArray Flex platform 129 
(Thermo Fisher, Waltham, MA USA). These arrays contain unique probes to 754 miR targets 130 
(plate IDs available from Thermo Fisher, Advanced microRNA panel, Waltham, MA, USA). 131 
Data were analysed using Thermo Fisher ‘Connect You’ lab software (Thermo Fisher 132 
Connect™, Thermo Fisher, Waltham, MA USA, (https://www.thermofisher.com). Target 133 
microRNAs demonstrating the largest fold changes across the treatments were selected for 134 
follow up (supplementary table S1 and S2).  135 
  136 




To assess pathway and gene targets for miRNAs dysregulated in response to individual 139 
aspects of the diabetic microenvironment, we used the DNA intelligent analysis (DIANA) 140 
mirPath v3.0 database and the DIANA-micro-T-CDS v 5.0 algorithm (25, 26). The DIANA 141 
mirPath database focuses on the identification of miRNA targeted cell pathways, the algorithm 142 
performs gene set enrichment analysis (GSEA) using a Fisher’s exact test to determine the 143 
statistical significance of microRNA gene targets in KEGG pathways, Benjamini Hochberg 144 
false discovery rate p value threshold set to 0.05. We first used this platform to carry out GSEA 145 
using the top 5 upregulated and the top 5 down-regulated miRNAs for each individual 146 
component of the diabetic microenvironment (high glucose, low glucose, hypoxia, 147 
inflammatory factors and palmitic acid).  148 
 149 
Validation of dysregulated miRNAs 150 
 151 
The top 10 miRNAs demonstrating dysregulation across 4 or more treatments were validated 152 
using Taqman® advanced miR assays (Thermo Fisher, Waltham, MA USA). The three 153 
miRNAs with the most stable expression patterns under test conditions in our initial analysis 154 
(miR 106b-3p, miR-191-3p and miR103-3p) were selected for use as endogenous controls. 155 
qRTPCR reaction mixes included 2.5 μL Taqman® Universal PCR mastermix II (no 156 
AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 157 
μL Taqman® gene assay (Thermo Fisher, Foster City USA) in a 5 μL reaction volume. Cycling 158 
conditions were: 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 seconds at 95 °C for 159 
30 s and 1 minute at 60 °C. Reactions were carried out in 3 biological replicates and 3 technical 160 
replicates. MicroRNA assay identifiers are given in supplementary table S2. The relative 161 
expression of each target miRNA was determined by the comparative Ct approach (27, 28) 162 
and were calculated relative to the geometric mean of the endogenous control genes. We also 163 
carried out an analysis relative to the global mean of expression across all transcripts tested 164 
as a separate validation. Expression levels were then normalised to the median level of 165 
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expression seen in untreated EndoC-βH1 cells. Differences in gene expression levels 166 
between mock-treated and treated EndoC-βH1 cells were compared to the same time point 167 
controls for each condition and investigated for statistical significance by student independent 168 
t-test carried out using SPSS version 23 (IBM, North Castle, NY, USA). Data were presented 169 
as means ± S.E.M. 170 
 171 
Pathway enrichment analysis for miRNAs responsive to 4 or more treatments 172 
 173 
Following validation of the 10 miRNAs showing evidence of dysregulation in response to >4 174 
of the diabetomimetic stimuli tested, we then carried out a miRNA pathway enrichment 175 
analysis to more closely examine the gene ontology pathways that may be enriched in the 176 
target genes of miRNAs responsive to multiple aspects of the diabetic microenvironment. The 177 
p value was set to 0.050 and MicroT threshold to 0.8. Each predicted target was given a 178 
microRNA target (MITG) score which predicts the probability of the microRNA targeting that 179 
gene. 180 
 181 
Validation of miRNA target gene mRNA levels 182 
 183 
Target genes for miRNAs demonstrating dysregulation in response to 4 or more of the cellular 184 
stressors tested were selected for validation were based on the MITG scores from the DIANA-185 
microT-CDS v5.0 algorithm (25). The MITG score is the predictive score, where the higher the 186 
score the higher the probability that the gene in question is a target of the miRNA on the basis 187 
of complementarity (29). A panel of 10 mRNAs were selected on the basis of highest MITG 188 
score, most statistically significant p value, number of genes predicted and number of miRNAs 189 
targeting the top 5 pathways showing enrichment for targets of dysregulated miRNAs.  190 
 191 
Target gene expression levels were then measured directly using quantitative RT-PCR 192 
performed using IDT mini primetime gene expression assays (Integrated DNA 193 
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Technologies, Skokie, Illinois, USA) as detailed in supplementary table S3. Reactions were 194 
carried out in triplicate on 384 well plates, using one assay per plate containing all samples. 195 
Each reaction included 2.5 μL Taqman® Universal PCR mastermix II (no AmpErase® UNG) 196 
(Thermo Fisher, Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene 197 
assay (Thermo Fisher, Foster City USA) in a 5 μL reaction volume. Cycling conditions were: 198 
50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 seconds at 95 °C for 30 s and 1 minute 199 
at 60 °C. Associations between miRNA and mRNA target expression were assessed using 200 
independent t tests carried out using SPSS v23 (IBM, North Castle, NY, USA). We identified 201 
correlations by integrating miRNA expression data with mRNA target expression to assess 202 
expression changes that occurred in response to the same cellular stresses. This method was 203 
used to assess relationships between the miRNA and mRNA, particularly where the predicted 204 
miRNA target gene expression was contrary to that of the miRNA (30-32). To account for 205 
comparisons between time points and controls we also carried out ANOVA using SPSS v24 206 





Dysregulation of miRNAs in response to aspects of the diabetic microenvironment 212 
 213 
391 out of 757 miRNAs tested were expressed in untreated EndoC-H1 human beta cells. 214 
170 of these demonstrated altered expression with greater than 2x fold change upon treatment 215 
with high (25mM) or low (2.5mM) glucose, palmitic acid (0.5mM), hypoxia (<3% O2) or 216 
cytokines (TNF, IFN, IL1) (Supplementary table S1). This equates to 23% of the miRNome 217 
tested.  218 
 219 





Although each treatment generally caused dysregulation of a specific and unique set of 223 
miRNAs (Supplementary table S1), the KEGG pathways that mRNA targets of those miRNAs 224 
were clustered in displayed surprising conservation (table 1). Despite the differing identity of 225 
miRNAs showing expression differences in response to the different tissues, the HIPPO 226 
pathway, the ‘Lysine degradation’ pathway, the ‘Proteoglycans in cancer’ and the ‘ErbB 227 
signalling pathway’ were all enriched in targets of dysregulated miRNAs for 4/5 of the 228 
treatments (table 1).  229 
 230 
Validation of miRNAs demonstrating evidence of dysregulation in response to 4 or more 231 
treatments 232 
 233 
Independent validation of the miRNAs demonstrating the largest fold changes in response to 234 
at least 4 treatments demonstrated that 5 miRNAs survived independent validation, see table 235 
2 and figure 1). MicroRNA miR-136-5p was altered in response to 25 mM high glucose and 236 
inflammatory factors TNFα, IL1-β and INFγ (p=0.008 mean diff 0.782, p=0.01 mean diff 1.047 237 
and p=0.002 mean diff -0.634 respectively). miR-299-5p showed altered expression in 238 
response to changes in glycaemia and hypoxia (p= 0.002 mean diff -0.619 and 0.01 mean diff 239 
-0.685 respectively). miR-454-5p responded to 2.5 mM low glucose (p= 0.012 mean diff 240 
4.145). Both miR-152 and miR-185 responded to 25 mM high glucose (p=0.005 mean diff 241 
0.536 and p=0.024 mean diff -2.221 respectively). To assess the changes in relation to the 242 
timepoints we carried further analysis by ANOVA which showed the same statistical hits as 243 
were identified by the t-tests (Supplementary table S4). 244 
 245 
The Lysine degradation, HIPPO and FOXO pathways are enriched in genes targeted by 246 




Given the conservation of pathways enriched in targets of dysregulated miRNAs, we then 249 
determined the gene ontology pathways enriched for genes targeted by miRNAs 250 
demonstrating common effects across treatments. The top 5 pathways targeted by these 251 
miRNAs were: Lysine degradation (p=3.0x10-3) with 9 gene targets predicted, HIPPO 252 
signalling pathway (p=5.84x10-5) with 17 predicted gene targets, FOXO signalling pathway 253 
(p=0.02) with 18 predicted gene targets, TGF - oestrogen (p=0.02) with 9 predicted gene 254 
targets and Pathways in Central Cancer (p=3.0x10-3) with 9 predicted gene targets, see table 255 
3.  256 
 257 
Correlation of miRNA and mRNA target expression  258 
  259 
To validate miRNA:target relationships, we correlated the mRNA expression level of the most 260 
highly predicted target gene from each of the top three pathways, with its respective miRNA 261 
as previously described (30-32). We found that changes in the expression of miR-136-5p, 262 
miR299-5p and miR-454-5p negatively correlated with expression changes in their respective 263 
target genes, MAPK1/ DLG2, PDK1 and MAPK1 in response to the cellular stressors tested, 264 
(table 4; figure 2). A positive correlation between miRNA and mRNA expression was also 265 




Cellular stresses such as those produced by diabetes or other metabolic disturbance are 270 
known to influence features of beta cell function (2) and affect the miRNA milieu (33-35). In 271 
the work described here, we present evidence that exposure to some features of the type 2 272 
diabetic microenvironment; altered glycaemia, dyslipidaemia, hypoxia and inflammatory 273 
agents, was associated with dysregulation of miRNA expression for five miRNAs including 274 
miR-136-5p, miR299-5p, miR-454-5p, miR-152 and miR-185. GSEA analysis revealed that 275 
predicted targets of these miRNAs may be clustered in FOXO, HIPPO, Lysine Degradation 276 
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and Central carbon in cancer pathways. We also demonstrated that whilst the specific miRNAs 277 
showing expression differences in response to different treatments were different, the 278 
pathways that were enriched in their targets showed surprising conservation. Gene target 279 
validation showed negative correlations between 3 miRNAs and their respective gene targets, 280 
miR-136-5p and MAPK1/ DLG2, miR299-5p and PDK1 and miR-454-5p and its predicted 281 
target MAPK1. These findings are consistent with previous studies reporting associations of 282 
specific miRNA with beta cell dysfunction and survival in human and rodent model systems 283 
and in our previous work in ex vivo human islets (34, 36-41).  284 
 285 
MicroRNAs have previously been implicated in cellular stress response; changes to the 286 
expression of the mir-375 (42) and the miR-200 families (43) have been demonstrated by 287 
others to have involvement in the regulation of apoptosis in response to oxidative stress (44) 288 
and in response to inflammatory factors (34, 45). Well-defined roles have also been described 289 
for miRNAs in glucose homeostasis (46, 47); miR-124, and miR-187 are known to target genes 290 
involved in beta cell proliferation (47, 48), whereas miR-375 and miR-7 are known to play roles 291 
in cell proliferation, differentiation and insulin production and secretion (47, 49, 50). 292 
MicroRNAs also have involvement in mediation of the unfolded folded response (51). The 293 
cross-regulatory relationship between cellular stress and miRNA expression renders these 294 
small non-coding RNA regulators uniquely poised to interface between the cellular 295 
microenvironment and beta cell function (8, 9, 34, 52, 53). A number of studies have 296 
demonstrated that exposure to these cellular stressors is also associated with disrupted beta 297 
cell function, particularly in relation to glucose sensitive insulin secretion (22, 54, 55). 298 
  299 
We found altered expression of miRNAs 136-5p, 299-5p, 152 and 185 which have been 300 
implicated in beta cell responses to cellular stress (12, 36, 37, 56-58). Reduced expression of 301 
miR-136-5p has been found in the islets of patients with T2D (59) with altered miR-299-5p 302 
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expression associated with beta cell failure and apoptosis in response to diabetes related 303 
stresses (12). Increased levels of miR-185 have recently been suggested to enhance insulin 304 
secretion and be protective from apoptosis, improving proliferation and viability (58). Bao et al 305 
note that miR-185 is downregulated in both patients with T2D and mouse models of the 306 
disease (36). Elevated levels of miR-152 have been seen in islets from patients with T2D (37) 307 
and it is known to be upregulated in hyperglycaemia as well as impaired glucose sensitive 308 
insulin secretion (GSIS) (35, 37, 46). These findings are consistent with a model whereby 309 
hyperglycaemia could result in impaired insulin secretion via miRNA regulation of key targets 310 
in beta cell function but that these miRNAs are also implicated in beta cell survival. We also 311 
noted biphasic miRNA expression across timepoints, a feature which has been previously 312 
described in the literature and which demonstrates how labile miRNA expression can be in 313 
response to cellular stressors (60-62).  314 
 315 
Validation of predicted targets identified from pathways analysis showed negative correlations 316 
for miR-454-5p and its predicted target MAPK1, miR-136-5p and its predicted target DLG2 317 
and miR-299-5p and its predicted target PDK1. Correlation analysis is a recognised technique 318 
for identifying potential roles for miRNA in gene regulation, with negative correlations being 319 
the most commonly observed phenomenon (31, 32). In the work presented here, target 320 
validation from pathways may support a model where microRNAs 454-5p, 136-5p and 299-5p 321 
could be influencing beta cell survival and rates of apoptosis in response to diabetes related 322 
cell stresses. Low glucose conditions were associated with a marked increase in expression 323 
of miR454-5p, compared to negligible levels in controls and significantly decreased expression 324 
of its target, MAPK1. MAPK1 signalling occurs in response to microenvironmental changes 325 
affecting cellular metabolism and is implicated in the pathogenesis of metabolic syndrome 326 
(38). Downregulation of MAPK1 leads to increased apoptosis (38) and so it is possible that 327 
miR-454-5p could be influencing rates of apoptosis during cellular stress (38, 39). Similarly 328 
reduced levels we found of miR-136-5p, with concomitant increases in its predicted target 329 
DLG2, associated with exposure to inflammatory factors may indicate a potential role in beta 330 
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cell survival. In a rat model of spinal cord injury, over expression of miR-136-5p promoted 331 
generation of proinflammatory cytokines while reduced expression was shown to be protective 332 
against inflammatory infiltrates (56, 59). Its target, DLG2 is a signalling protein within the 333 
HIPPO pathway (20) which is important for beta cell differentiation, survival and proliferation 334 
and interacts with MAPK and PI3K-AKT pathways (20). The increased levels of expression 335 
we observed are suggestive of a role for miR-136-5p in the regulation of beta cell survival 336 
during inflammation.   337 
 338 
miR-299-5p has been associated with tumorigenesis and regulation of apoptosis in colorectal 339 
cancer as well as being neuroprotective via inhibition of autophagy in mouse models of 340 
Alzheimers disease (12). A study using mouse models also showed that reduced expression 341 
of miR-299-5p in response to glucolipotoxicity resulted in beta cell failure and apoptosis (12, 342 
57).   Here, exposure to <3% O2 hypoxic conditions induced reduced expression of miR-299, 343 
with increased expression of its target PDK1 which has well established roles in beta cell 344 
stress response in relation to insulin signalling, survival and apoptosis with ablation resulting 345 
in a diabetic phenotype in mice (40).  PDK1 forms part of the PI3K-PDK1-AKT signalling 346 
pathway, part of the central carbon metabolism in cancer KEGG pathway, which has been 347 
shown in mouse models to mediate potentiation of insulin secretion and beta cell survival (41). 348 
Studies in mouse models have also shown that hypoxia inducible factor HIF1 activates 349 
transcription of PDK1 to increase lactate secretion (63), outlining its pivotal role in beta cell 350 
stress response. These data suggest that miRNAs may be involved in coordinating beta cell 351 
stress responses particularly in relation to beta cell survival and rates of apoptosis.  352 
 353 
Patterns of islet miRNA expression in patients with T2D compared with euglycaemic controls 354 
are comparable with the changes that we have observed in our study; our data on miR-185, 355 
miR-152, miR-299-5p, miR-376a and miR-136-5p are in agreement with other studies in ex 356 
vivo islet samples (10, 35, 46, 64, 65), despite the heterogeneity between studies, which may 357 
arise from differences in islet handling and cell culture techniques (35). Our study differs from 358 
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previous work in that it uses a completely humanised culture system for assessment of effects 359 
and it assesses specific subcomponents of the diabetic microenvironment in isolation. 360 
Although sequence conservation between the human and rodent miRNA portfolios is 361 
reasonable (66), the timing and localisation of miRNA expression is not well conserved 362 
between vertebrate species (67). Accordingly, assessment of diabetes-related miRNA 363 
changes has revealed differences between rodent and human datasets (34, 68). Added to 364 
this, the short and degenerate nature of miRNA binding sites means that miRNA:mRNA target 365 
conservation is often poor to the extent that the changing nature of miRNA target sites has 366 
been suggested as a source of organismal diversity (69). This means that the predicted effects 367 
of diabetes-induced miRNA dysregulation may differ between animal models and humans, 368 
and care should be taken in extrapolating conclusions between species.  An important next 369 
step would be to follow up these findings in relation to effects on target protein levels and cell 370 
signalling pathways. However, this falls outside the scope of this present study. 371 
 372 
In conclusion, we have shown evidence that exposure to cellular stressors commonly 373 
associated with a diagnosis of type 2 diabetes in a humanised Endo-H1 culture system may 374 
target genes which are enriched in a core set of pathways. The expression of three 375 
dysregulated miRNAs, miR-454-5p, miR136-5p and miR-299-5p, correlate with expression 376 
changes in their predicted target genes which are enriched in FOXO and MAPK pathways and 377 
are known to be involved in regulation of beta cell survival in response to cell stress, 378 
proliferation, differentiation and apoptosis (38, 39, 70). These data may suggest that the beta 379 
cell stress response, particularly in relation to beta cell survival, could possibly be coordinated 380 
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Table 1: Gene Ontology pathways enriched in targets of miRNAs dysregulated by different aspects of the diabetic microenvironment. 572 
The top 15 pathways enriched in target genes of miRNAs showing evidence of dysregulation in response to different cell treatments is given 573 
here. P values are FDR adjusted. No. Genes = Number of genes targeted in pathway. No. miRNA = number of miRNAs targeting that 574 
pathway. Pathways highlighted in italic type are common to 3 or more treatments, pathways highlighted in bold typeface are common to 4. 575 
 576 
Pathway FDR corrected p value No. Genes No. miRNA 
 
25mM Glucose 
TGF-beta signaling pathway 1.52E-07 34 7 
Mucin type O-Glycan biosynthesis 2.61E-07 10 5 
GABAergic synapse 1.63E-06 22 8 
Signaling pathways regulating pluripotency of stem cells 2.33E-06 50 9 
Proteoglycans in cancer 3.40E-06 61 9 
Hippo signaling pathway 8.43E-05 43 7 
Lysine degradation 8.54E-05 16 7 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 9.86E-05 25 7 
N-Glycan biosynthesis 0.0003 15 5 
Adrenergic signaling in cardiomyocytes 0.0004 43 8 
FoxO signaling pathway 0.0008 41 8 
MAPK signaling pathway 0.001 73 8 
Biosynthesis of unsaturated fatty acids 0.001 5 3 
Morphine addiction 0.002 28 8 
ErbB signaling pathway 0.002 31 9 
 
2.5mM Glucose 
Proteoglycans in cancer 8.46E-09 75 10 
Mucin type O-Glycan biosynthesis 2.19E-08 12 9 
Axon guidance 6.19E-08 62 10 
Nicotine addiction 3.77E-07 19 8 
ErbB signaling pathway 2.09E-06 40 9 
Lysine degradation 4.95E-05 20 9 
Ras signaling pathway 0.0002 87 10 
Glioma 0.0002 28 10 
Amphetamine addiction 0.0005 28 9 
Endometrial cancer 0.0005 25 10 
24 
 
N-Glycan biosynthesis 0.0007 20 7 
TGF-beta signaling pathway 0.0007 32 9 
Hippo signaling pathway 0.0007 52 9 
Neurotrophin signaling pathway 0.0008 51 10 
Focal adhesion 0.0008 78 10 
 
<3% O2 
Proteoglycans in cancer 3.52E-07 47 8 
TGF-beta signaling pathway 5.60E-07 20 5 
Axon guidance 6.85E-07 38 9 
FoxO signaling pathway 2.50E-05 37 8 
Endocytosis 5.43E-05 51 8 
Neurotrophin signaling pathway 9.97E-05 35 7 
Colorectal cancer 0.00012 20 6 
Lysine degradation 0.0002 11 5 
Hepatitis B 0.0002 29 7 
RNA degradation 0.002 24 7 
Protein processing in endoplasmic reticulum 0.002 38 9 
MAPK signaling pathway 0.002 56 8 
Mucin type O-Glycan biosynthesis 0.003 6 6 
ErbB signaling pathway 0.004 23 7 
Prolactin signaling pathway 0.004 19 7 
 
0.5mM Palmitic Acid 
Prion diseases 4.55E-12 7 6 
Lysine degradation 7.12E-05 18 7 
ErbB signaling pathway 0.0002 33 9 
Nicotine addiction 0.0012 14 8 
Circadian entrainment 0.0011 34 10 
Inflammatory mediator regulation of TRP channels 0.0013 31 9 
Amphetamine addiction 0.0013 23 9 
Morphine addiction 0.0013 28 9 
Glioma 0.0013 22 9 
Dopaminergic synapse 0.0012 43 10 
Glutamatergic synapse 0.0023 37 10 
Proteoglycans in cancer 0.003 58 10 
Long-term potentiation 0.004 26 9 
Hippo signaling pathway 0.004 34 7 
Rap1 signaling pathway 0.004 60 10 
 
TNFα (1000 U/ mL, INFγ (750 U/ mL) and IL1β (75 U/ mL) 
25 
 
Hippo signaling pathway 0.002 35 7 
Adrenergic signaling in cardiomyocytes 0.002 43 9 
cGMP-PKG signaling pathway 0.002 51 10 
Glutamatergic synapse 0.002 33 7 
Amphetamine addiction 0.002 22 8 
cAMP signaling pathway 0.002 57 9 
Vascular smooth muscle contraction 0.002 35 10 
Wnt signaling pathway 0.002 39 8 
Signaling pathways regulating pluripotency of stem cells 0.004 39 8 
Endocrine and other factor-regulated calcium reabsorption 0.007 15 6 
Axon guidance 0.007 32 7 
Dopaminergic synapse 0.011 38 9 
Transcriptional misregulation in cancer 0.014 43 8 
mRNA surveillance pathway 0.014 27 5 
Estrogen signaling pathway 0.017 26 8 
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Table 2. Targeted expression of most altered microRNAs high throughput global microRNA screen. The p values for statistical significance 578 
as determined by independent t-test, Mean difference, Standard errors of measurement (SED) and the 95% confidence intervals are given below. 579 
Results significant below the Bonferroni threshold for correction for 4 treatments (glucose, hypoxia, dyslipidaemia and inflammatory factors) (p = 580 
0.013) are given in bold italic type, those showing nominal significance only are given in italic underlined type.  581 
 582 
25 mM glucose Independent Samples Test- t- test p = 0.016 
24 hrs 36 hrs 48 hrs 
 p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI 
    Lower Upper     Lower Upper     Lower Upper 
miR-185-3p 0.297 -0.743 0.675 -2.247 0.762 miR-185-3p 0.024 -2.221 0.820 -4.076 -0.366 miR-185-3p 0.035 -1.629 0.667 -3.116 -0.142 
miR-885-5p 0.646 0.226 0.470 -0.886 1.338 miR-885-5p 0.98 0.007 0.272 -0.609 0.624 miR-885-5p 0.575 0.226 0.387 -0.665 1.118 
miR-27b-3p 0.999 0.000 0.184 -0.411 0.411 miR-27b-3p 0.113 0.312 0.179 -0.088 0.711 miR-27b-3p 0.116 0.312 0.181 -0.091 0.715 
miR-124-3p 0.206 0.296 0.219 -0.192 0.783 miR-124-3p 0.819 0.053 0.226 -0.450 0.556 miR-124-3p 0.592 -0.120 0.216 -0.601 0.362 
miR-136-5p 0.252 0.318 0.262 -0.266 0.902 miR-136-5p 0.008 0.782 0.236 0.257 1.306 miR-136-5p 0.571 0.143 0.244 -0.400 0.685 
miR-152-3p 0.448 -0.141 0.179 -0.539 0.257 miR-152-3p 0.005 0.536 0.148 0.206 0.866 miR-152-3p 0.111 0.288 0.165 -0.079 0.655 
miR-299-5p 0.002 -0.619 0.139 -0.933 -0.304 miR-299-5p 0.035 -0.255 0.103 -0.487 -0.023 miR-299-5p 0.155 0.164 0.106 -0.075 0.404 
miR-576-5p 0.514 -0.322 0.464 -1.456 0.813 miR-576-5p 0.101 -0.514 0.266 -1.164 0.136 miR-576-5p 0.032 -0.683 0.224 -1.275 -0.091 
miR-93-5p 0.232 0.263 0.207 -0.197 0.724 miR-93-5p 0.097 0.395 0.216 -0.086 0.876 miR-93-5p 0.073 0.446 0.223 -0.050 0.942 
2.5 mM glucose Independent Samples Test- t- test p = 0.016 
24 hrs 36 hrs 48 hrs 
 p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI 
miR-185-3p 0.188 -1.019 0.721 -2.626 0.587 miR-185-3p 0.146 -3.828 1.737 -10.675 3.019 miR-185-3p 0.108 -5.380 2.020 -13.523 2.763 
miR-885-5p 0.188 -2.368 1.677 -6.105 1.368 miR-885-5p 0.325 0.905 0.862 -1.082 2.892 miR-885-5p 0.924 -0.184 1.876 -4.365 3.997 
miR-454-5p 0.62 0.781 1.529 -2.625 4.187 miR-454-5p 0.033 3.320 1.346 0.321 6.318 miR-454-5p 0.012 4.145 1.350 1.138 7.153 
miR-27b-3p 0.188 0.311 0.220 -0.179 0.801 miR-27b-3p 0.922 0.024 0.239 -0.508 0.556 miR-27b-3p 0.349 0.211 0.215 -0.267 0.690 
miR-124-3p 0.689 -0.122 0.296 -0.782 0.538 miR-124-3p 0.056 -0.614 0.284 -1.247 0.020 miR-124-3p 0.521 -0.203 0.305 -0.882 0.476 
miR-136-5p 0.075 0.518 0.260 -0.062 1.097 miR-136-5p 0.84 -0.056 0.269 -0.656 0.544 miR-136-5p 0.69 0.124 0.301 -0.548 0.795 
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miR-152-3p 0.637 -0.125 0.257 -0.697 0.447 miR-152-3p 0.299 -0.251 0.229 -0.762 0.260 miR-152-3p 0.239 0.288 0.230 -0.225 0.800 
miR-299-5p 0.49 0.831 1.159 -1.752 3.414 miR-299-5p 0.457 0.897 1.160 -1.687 3.482 miR-299-5p 0.539 0.739 1.161 -1.848 3.326 
miR-576-5p 0.352 1.439 1.475 -1.846 4.725 miR-576-5p 0.237 1.044 0.818 -0.839 2.928 miR-576-5p 0.946 -0.117 1.676 -3.852 3.618 
miR-93-5p 0.332 0.244 0.239 -0.289 0.778 miR-93-5p 0.873 -0.042 0.257 -0.614 0.530 miR-93-5p 0.551 0.145 0.235 -0.378 0.668 
<3% O2 Independent Samples Test- t- test p = 0.016 
4 hrs 12 hrs 24 hrs 
 p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI 
    Lower Upper     Lower Upper     Lower Upper 
miR-27b-3p 0.14 -0.411 0.262 -0.977 0.155 miR-27b-3p 0.387 -0.229 0.256 -0.781 0.323 miR-27b-3p 0.18 -0.353 0.249 -0.891 0.185 
miR-124-3p 0.065 1.816 0.852 -0.139 3.770 miR-124-3p 0.168 1.301 0.866 -0.665 3.268 miR-124-3p 0.389 1.083 1.215 -1.542 3.708 
miR-136-5p 0.52 0.441 0.668 -1.001 1.884 miR-136-5p 0.468 0.502 0.672 -0.949 1.953 miR-136-5p 0.486 0.493 0.686 -0.990 1.975 
miR-152-3p 0.142 -0.336 0.209 -0.807 0.135 miR-152-3p 0.511 -0.141 0.205 -0.607 0.326 miR-152-3p 0.11 -0.472 0.276 -1.068 0.123 
miR-299-5p 0.01 -0.685 0.220 -1.171 -0.200 miR-299-5p 0.035 -0.532 0.221 -1.020 -0.045 miR-299-5p 0.182 -0.373 0.265 -0.945 0.199 
miR-93-5p 0.102 -0.396 0.217 -0.889 0.097 miR-93-5p 0.229 -0.282 0.218 -0.777 0.213 miR-93-5p 0.097 -0.483 0.270 -1.067 0.101 
miR-21-3p 0.238 0.826 0.650 -0.660 2.311 miR-21-3p 0.171 0.976 0.652 -0.512 2.464 miR-21-3p 0.265 0.771 0.645 -0.710 2.253 
0.5 mM Palmitic acid Independent Samples Test- t- test p = 0.016 
12 hrs 24 hrs 48 hrs 
 p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
    Lower Upper     Lower Upper     Lower Upper 
miR-185-3p 0.147 2.754 1.749 -1.144 6.651 miR-185-3p 0.992 -0.017 1.772 -3.966 3.931 miR-185-3p 0.368 1.731 1.835 -2.357 5.820 
miR-885-5p 0.819 0.062 0.266 -0.531 0.656 miR-885-5p 0.634 -0.146 0.297 -0.809 0.516 miR-885-5p 0.046 -0.522 0.230 -1.034 -0.010 
miR-27b-3p 0.682 -0.184 0.435 -1.152 0.785 miR-27b-3p 0.693 0.194 0.478 -0.872 1.260 miR-27b-3p 0.454 0.341 0.438 -0.635 1.318 
miR-124-3p 0.814 -0.053 0.218 -0.540 0.434 miR-124-3p 0.651 -0.103 0.220 -0.594 0.388 miR-124-3p 0.226 0.228 0.169 -0.186 0.641 
miR-136-5p 0.803 -0.060 0.235 -0.583 0.463 miR-136-5p 0.79 0.110 0.401 -0.783 1.002 miR-136-5p 0.002 1.047 0.259 0.469 1.624 
miR-152-3p 0.357 -0.213 0.221 -0.705 0.279 miR-152-3p 0.563 0.160 0.268 -0.437 0.757 miR-152-3p 0.17 0.450 0.305 -0.229 1.129 
miR-299-5p 0.076 -0.242 0.122 -0.515 0.030 miR-299-5p 0.86 -0.055 0.305 -0.736 0.625 miR-299-5p 0.415 0.178 0.209 -0.287 0.642 
miR-576-5p 0.508 -0.192 0.280 -0.816 0.432 miR-576-5p 0.368 1.650 1.440 -4.412 7.712 miR-576-5p 0.129 -0.408 0.230 -0.978 0.163 
miR-93-5p 0.794 -0.112 0.417 -1.042 0.818 miR-93-5p 0.683 0.201 0.479 -0.867 1.269 miR-93-5p 0.371 0.416 0.444 -0.574 1.406 
proinflammatory cytokines Independent Samples Test- t- test p = 0.016 
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12 hrs 24 hrs 36 hrs 
 p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI  p value Mean diff. SED 95% CI 
    Lower Upper     Lower Upper     Lower Upper 
miR-885-5p 0.993 0.004 0.380 -0.857 0.864 miR-885-5p 0.773 -0.130 0.436 -1.116 0.856 miR-885-5p 0.121 0.667 0.389 -0.214 1.547 
miR-454-5p 0.583 0.198 0.342 -0.638 1.034 miR-454-5p 0.702 -0.107 0.265 -0.755 0.542 miR-454-5p 0.57 -0.166 0.278 -0.823 0.492 
miR-27b-3p 0.477 0.294 0.398 -0.593 1.180 miR-27b-3p 0.706 0.155 0.400 -0.737 1.048 miR-27b-3p 0.481 0.291 0.398 -0.595 1.178 
miR-124-3p 0.146 0.411 0.261 -0.170 0.992 miR-124-3p 0.336 0.254 0.251 -0.305 0.813 miR-124-3p 0.55 0.148 0.240 -0.385 0.682 
miR-136-5p 0.002 -0.634 0.156 -0.982 -0.286 miR-136-5p 0.562 0.190 0.282 -0.890 1.269 miR-136-5p 0.266 -0.547 0.368 -2.020 0.926 
miR-152-3p 0.674 -0.069 0.158 -0.422 0.284 miR-152-3p 0.756 -0.060 0.188 -0.480 0.360 miR-152-3p 0.544 -0.251 0.353 -1.633 1.131 
miR-299-5p 0.822 0.036 0.154 -0.308 0.379 miR-299-5p 0.152 -0.302 0.194 -0.735 0.132 miR-299-5p 0.371 0.128 0.137 -0.177 0.433 
miR-576-5p 0.798 0.040 0.154 -0.302 0.383 miR-576-5p 0.194 0.276 0.198 -0.165 0.717 miR-576-5p 0.157 0.269 0.176 -0.123 0.660 







Table 3. mRNA targets identified from DIANA pathways analysis. 587 
 588 
5 microRNAs were found to be differentially regulated upon validation and these were selected 589 
for DIANA pathways analysis. Target genes were selected on the basis of pathway p value 590 
and MITG score, which determines the probability of the microRNA targeting a specific gene.  591 
 592 
 593 
Gene Pathway FDR corrected p-value MITG score(s) 
KMT2C Lysine degradation 3.00 x 10-3 0.97 
BCL2L11 FOXO 0.02 0.99 
DLG2 Hippo 5.84 x 10-5 0.92 
SP1 TGF and Estrogen 0.02 0.99 
SOD FOXO 0.02 0.98 
MAPK1 FOXO 0.02 0.90 
TEAD1 Hippo 5.84 x 10-5 0.85 
SERPINE1 Hippo 5.84 x 10-5 0.82 
MOB1A Hippo 5.84 x 10-5 0.82 
PDK1 Central carbon cancer 3.00 x 10-3 0.82 
 594 
  595 
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Table 4. Validated of gene targets identified from DIANA pathways analysis. The p values 596 
for statistical significance as determined by independent t-test, Mean difference, Standard 597 
errors of measurement (SED) and the 95% confidence intervals are given below. Bold italic 598 
p<0.050 Gene list is a priori and single test applied so no correction for multiple testing. 599 
 600 
25 mM high glucose Independent Samples Test p = 0.050 
Gene p value Mean Diff. SED 95% CI 
    Lower Upper 
BCL211 0.392 0.060 0.066 -0.096 0.217 
DLG2 0.215 0.184 0.135 -0.135 0.504 
KMT2C 0.451 -0.069 0.087 -0.275 0.136 
MAPK1 0.099 -0.048 0.025 -0.107 0.012 
MOB1A 0.263 -0.075 0.061 -0.219 0.070 
PDK1 0.373 0.094 0.099 -0.140 0.328 
SERPINE1 0.11 0.085 0.046 -0.025 0.194 
SOD1-1 0.024 -0.085 0.030 -0.155 -0.015 
SP1 0.367 -0.064 0.067 -0.222 0.093 
TEAD1 0.682 -0.033 0.077 -0.216 0.150 
2.5 mM low glucose Independent Samples Test p = 0.050 
Gene p value Mean Diff. SED 95% CI 
    Lower Upper 
BCL211 0.206 0.083 0.060 -0.058 0.225 
DLG2 0.122 0.234 0.133 -0.080 0.549 
KMT2C 0.259 -0.054 0.044 -0.158 0.050 
MAPK1 0.039 -0.117 0.046 -0.226 -0.007 
MOB1A 0.117 -0.103 0.057 -0.238 0.033 
PDK1 0.179 0.151 0.101 -0.088 0.391 
SERPINE1 0.448 0.037 0.046 -0.071 0.145 
SOD1-1 0.957 -0.002 0.037 -0.090 0.086 
SP1 0.475 -0.052 0.069 -0.216 0.111 
TEAD1 0.931 -0.007 0.077 -0.190 0.176 
Hypoxia Independent Samples Test p=0.050 
Gene p value Mean Diff. SED 95% CI 
    Lower Upper 
BCL211 0.266 -0.088 0.072 -0.264 0.088 
DLG2 0.004 -0.457 0.091 -0.689 -0.225 
KMT2C 0.934 0.005 0.057 -0.135 0.145 
MAPK1 0.153 0.054 0.033 -0.027 0.134 
MOB1A 0.449 -0.058 0.072 -0.233 0.117 
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PDK1 0.0003 0.873 0.121 0.577 1.170 
SERPINE1 0.285 -0.082 0.070 -0.254 0.089 
SOD1-1 0.025 -0.077 0.025 -0.140 -0.013 
SP1 0.95 0.005 0.083 -0.197 0.208 
TEAD1 0.525 0.071 0.105 -0.186 0.328 
0.5 mM Palmitic Acid Independent Samples Test p=0.050 
Gene p value Mean Diff. SED 95% CI 
    Lower Upper 
BCL211 0.692 0.023 0.057 -0.110 0.157 
DLG2 0.598 0.073 0.133 -0.240 0.387 
KMT2C 0.06 -0.138 0.061 -0.283 0.007 
MAPK1 0.252 -0.031 0.025 -0.090 0.028 
MOB1A 0.13 -0.099 0.057 -0.234 0.037 
PDK1 0.023 0.281 0.097 0.053 0.510 
SERPINE1 0.423 0.043 0.050 -0.076 0.161 
SOD1-1 0.905 0.005 0.040 -0.090 0.099 
SP1 0.882 -0.010 0.068 -0.171 0.150 
TEAD1 0.51 0.054 0.078 -0.130 0.237 
Pro-inflammatory cytokines Independent Samples Test p=0.050 
Gene p value Mean Diff. SED 95% CI 
    Lower Upper 
BCL211 0.766 0.015 0.049 -0.101 0.132 
DLG2 0.032 0.267 0.095 0.032 0.502 
KMT2C 0.861 -0.014 0.076 -0.193 0.165 
MAPK1 0.729 -0.012 0.034 -0.094 0.069 
MOB1A 0.104 -0.104 0.056 -0.236 0.028 
PDK1 0.407 0.086 0.097 -0.144 0.315 
SERPINE1 0.746 -0.017 0.051 -0.138 0.104 
SOD1-1 0.741 -0.014 0.040 -0.110 0.082 
SP1 0.273 -0.102 0.085 -0.304 0.100 
TEAD1 0.615 0.045 0.085 -0.156 0.246 
 601 
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Figure Legends 604 
 605 
 606 
Figure 1. Targeted miRNA expression of most altered miRNAs from high throughput 607 
global miRNA screen. Larger dotted line shows significance p=<0.016. Bonferroni multiple 608 
testing correction for 3 tests. Coloured shapes denote significance. Smaller dotted line shows 609 
significance p -<0.050 no correction for multiple testing. Circles: 25 mM high glucose. Squares: 610 
2.5 mM low glucose. Diamonds: <3% O2. Triangles: 0.5 mM palmitic acid. Stars pro-611 
inflammatory factors. 612 
 613 
Figure 2. mRNA expression of predicted target genes from DIANA pathways analysis. 614 
Target genes are given on the X axis. Transcript expression expressed relative to endogenous 615 
controls and normalised to mock treated cells given on the Y axis. Smaller dotted line shows 616 
significance p= <0.050. Null effect given by solid line, p = 0.05 indicated by dotted line. Blue 617 
circles: 25 mM high glucose. Green squares: 2.5 mM low glucose. Red diamonds: <3% O2. 618 
Purple triangles: 0.5 mM palmitic acid. Inverse triangles: inflammatory factors, dark purple 619 
p=0.050. Pink inverse triangles: pro-inflammatory factors. 620 
 621 
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Figure 2 628 
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Supplementary tables 631 
Supplementary table S1. Table showing fold changes for microRNA expression from the high throughput global screen. Only those with 632 
fold change > 2.0 shown. MicroRNAs were selected for pathways analysis on the basis of being the most dysregulated microRNAs across 4 or 633 
more cell insult assays.  Assay IDs are also given. MicroRNAs selected for experimental follow up on the basis of dysregulation in response to > 634 





Sample name Target name Fold change 
25 mM glucose 478532_mir_hsa-miR-23a-3p 412.56 
25 mM glucose 478238_mir_hsa-miR-374a-5p 184.64 
25 mM glucose 478514_mir_hsa-miR-147a 165.77 
25 mM glucose 479087_mir_hsa-miR-606 156.2 
25 mM glucose 478826_mir_hsa-miR-323b-5p 114.78 
25 mM glucose 478620_mir_hsa-miR-101-5p 91.85 
25 mM glucose 477895_mir_hsa-miR-1290 84.06 
25 mM glucose 477962_mir_hsa-miR-19b-1-5p 75.86 
25 mM glucose 478411_mir_ath-miR159a 71.98 
25 mM glucose 477833_mir_hsa-miR-548d-3p 36.17 
25 mM glucose 478790_mir_hsa-miR-296-3p 20.98 
25 mM glucose 479041_mir_hsa-miR-556-3p 17.71 
25 mM glucose 477913_mir_hsa-miR-144-3p 16.17 
25 mM glucose 477863_mir_hsa-miR-101-3p 12.18 
25 mM glucose 479067_mir_hsa-miR-585-3p 11.23 
25 mM glucose 478307_mir_hsa-miR-136-5p 10.74 
25 mM glucose 478065_mir_hsa-miR-365a-3p 10.42 
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25 mM glucose 478588_mir_hsa-miR-320b 10.29 
25 mM glucose 478753_mir_hsa-miR-200b-5p 9.17 
25 mM glucose 478389_mir_hsa-miR-374b-5p 8.91 
25 mM glucose 477879_mir_hsa-miR-124-3p 8.42 
25 mM glucose 478091_mir_hsa-miR-424-3p 8.05 
25 mM glucose 478087_mir_hsa-miR-412-3p 7.35 
25 mM glucose 478177_mir_hsa-miR-616-3p 6.88 
25 mM glucose 478349_mir_hsa-miR-378a-3p 6.65 
25 mM glucose 477951_mir_hsa-miR-191-3p 6.57 
25 mM glucose 478581_mir_hsa-miR-135a-5p 6.54 
25 mM glucose 479073_mir_hsa-miR-589-5p 6.4 
25 mM glucose 478134_mir_hsa-miR-493-3p 6.07 
25 mM glucose 478200_mir_hsa-miR-744-5p 6.06 
25 mM glucose 478490_mir_hsa-miR-200a-3p 5.47 
25 mM glucose 479131_mir_hsa-miR-651-5p 5.35 
25 mM glucose 478745_mir_hsa-miR-196a-3p 5.2 
25 mM glucose 477936_mir_hsa-miR-183-3p 4.79 
25 mM glucose 479448_mir_hsa-miR-30a-5p 4.42 
25 mM glucose 478691_mir_hsa-miR-1292-5p 4.38 
25 mM glucose 477991_mir_hsa-miR-23b-5p 4.06 
25 mM glucose 477976_mir_hsa-miR-216a-5p 3.96 
25 mM glucose 477942_mir_hsa-miR-188-3p 3.96 
25 mM glucose 478855_mir_hsa-miR-374a-3p 3.93 
25 mM glucose 478231_mir_hsa-miR-199a-5p 3.6 
25 mM glucose 479469_mir_hsa-miR-625-5p 3.52 
25 mM glucose 478209_mir_hsa-miR-93-3p 3.38 
25 mM glucose 479207_mir_hsa-miR-92b-5p 3.37 
25 mM glucose 478951_mir_hsa-miR-500a-3p 3.27 
25 mM glucose 478273_mir_hsa-miR-30a-3p 3.26 
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25 mM glucose 478215_mir_hsa-miR-96-5p 3.13 
25 mM glucose 478367_mir_hsa-miR-590-5p 2.95 
25 mM glucose 479178_mir_hsa-miR-770-5p 2.7 
25 mM glucose 478105_mir_hsa-miR-448 2.66 
25 mM glucose 478827_mir_hsa-miR-32-3p 2.63 
25 mM glucose 478041_mir_hsa-miR-340-3p 2.62 
25 mM glucose 478132_mir_hsa-miR-491-5p 2.58 
25 mM glucose 478153_mir_hsa-miR-542-3p 2.55 
25 mM glucose 478142_mir_hsa-miR-501-5p 2.51 
25 mM glucose 477908_mir_hsa-miR-140-3p 2.37 
25 mM glucose 478755_mir_hsa-miR-202-5p 2.33 
25 mM glucose 477804_mir_hsa-miR-20b-5p 2.27 
25 mM glucose 478035_mir_hsa-miR-337-3p 2.23 
25 mM glucose 479150_mir_hsa-miR-665 2.18 
25 mM glucose 477943_mir_hsa-miR-188-5p 2.1 
25 mM glucose 478655_mir_hsa-miR-1250-5p 2.05 
25 mM glucose 478749_mir_hsa-miR-198 2.02 
Down regulated 
Sample name Target name Fold change 
25 mM glucose 478591_mir_hsa-miR-302b-3p >500 
25 mM glucose 479224_mir_hsa-miR-99a-3p >500 
25 mM glucose 478719_mir_hsa-miR-148b-5p 500 
25 mM glucose 479003_mir_hsa-miR-454-5p 200 
25 mM glucose 478786_mir_hsa-miR-25-5p 125.00 
25 mM glucose 477921_mir_hsa-miR-152-3p 52.63 
25 mM glucose 478732_mir_hsa-miR-185-3p 37.04 
25 mM glucose 477952_mir_hsa-miR-191-5p 26.32 
25 mM glucose 478439_mir_hsa-let-7d-5p 22.73 
25 mM glucose 478165_mir_hsa-miR-576-5p 21.74 
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25 mM glucose 479186_mir_hsa-miR-876-3p 16.95 
25 mM glucose 478793_mir_hsa-miR-299-5p 16.39 
25 mM glucose 478207_mir_hsa-miR-885-5p 15.38 
25 mM glucose 478240_mir_hsa-miR-376a-3p 14.29 
25 mM glucose 478078_mir_hsa-miR-382-5p 12.05 
25 mM glucose 478210_mir_hsa-miR-93-5p 11.90 
25 mM glucose 478270_mir_hsa-miR-27b-3p 11.11 
25 mM glucose 477980_mir_hsa-miR-219a-5p 9.62 
25 mM glucose 477851_mir_hsa-miR-130a-3p 8.93 
25 mM glucose 477931_mir_hsa-miR-16-2-3p 8.40 
25 mM glucose 478203_mir_hsa-miR-769-5p 7.52 
25 mM glucose 478068_mir_hsa-miR-369-5p 6.90 
25 mM glucose 478138_mir_hsa-miR-497-5p 6.90 
25 mM glucose 478060_mir_hsa-miR-363-3p 6.62 
25 mM glucose 480871_mir_hsa-miR-133b 6.58 
25 mM glucose 477902_mir_hsa-miR-136-3p 6.45 
25 mM glucose 478779_mir_hsa-miR-222-5p 6.37 
25 mM glucose 477932_mir_hsa-miR-17-3p 5.92 
25 mM glucose 478788_mir_hsa-miR-26a-2-3p 5.92 
25 mM glucose 478197_mir_hsa-miR-708-5p 5.65 
25 mM glucose 477899_mir_hsa-miR-130b-5p 5.62 
25 mM glucose 478012_mir_hsa-miR-31-3p 5.56 
25 mM glucose 479024_mir_hsa-miR-548n 5.56 
25 mM glucose 478690_mir_hsa-miR-1291 5.35 
25 mM glucose 477929_mir_hsa-miR-15b-3p 4.95 
25 mM glucose 477996_mir_hsa-miR-26b-3p 4.95 
25 mM glucose 478156_mir_hsa-miR-544a 4.24 
25 mM glucose 479035_mir_hsa-miR-551b-5p 4.20 
25 mM glucose 478015_mir_hsa-miR-31-5p 4.18 
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25 mM glucose 479059_mir_hsa-miR-579-3p 4.18 
25 mM glucose 477825_mir_hsa-miR-301b-3p 4.07 
25 mM glucose 478139_mir_hsa-miR-499a-5p 3.97 
25 mM glucose 477959_mir_hsa-miR-197-3p 3.88 
25 mM glucose 478544_mir_hsa-miR-129-2-3p 3.77 
25 mM glucose 479229_mir_hsa-miR-29c-3p 3.56 
25 mM glucose 478584_mir_hsa-miR-18b-5p 3.50 
25 mM glucose 477928_mir_hsa-miR-15a-3p 3.46 
25 mM glucose 477824_mir_hsa-miR-148b-3p 3.41 
25 mM glucose 478422_mir_hsa-miR-486-3p 3.41 
25 mM glucose 478181_mir_hsa-miR-628-3p 3.40 
25 mM glucose 478159_mir_hsa-miR-551b-3p 3.22 
25 mM glucose 478511_mir_hsa-miR-133a-3p 3.13 
25 mM glucose 478003_mir_hsa-miR-29b-2-5p 3.09 
25 mM glucose 478317_mir_hsa-miR-20a-3p 3.08 
25 mM glucose 478626_mir_hsa-miR-1179 3.08 
25 mM glucose 478326_mir_hsa-miR-370-3p 3.03 
25 mM glucose 478889_mir_hsa-miR-431-5p 3.00 
25 mM glucose 477887_mir_hsa-miR-126-3p 2.99 
25 mM glucose 478479_mir_hsa-miR-33b-5p 2.93 
25 mM glucose 479002_mir_hsa-miR-545-3p 2.93 
25 mM glucose 478128_mir_hsa-miR-486-5p 2.83 
25 mM glucose 478727_mir_hsa-miR-16-1-3p 2.82 
25 mM glucose 478778_mir_hsa-miR-221-5p 2.64 
25 mM glucose 478157_mir_hsa-miR-548a-3p 2.58 
25 mM glucose 478582_mir_hsa-miR-135b-5p 2.53 
25 mM glucose 477973_mir_hsa-miR-21-3p 2.48 
25 mM glucose 478583_mir_hsa-miR-181b-5p 2.48 
25 mM glucose 478126_mir_hsa-miR-485-5p 2.46 
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25 mM glucose 478178_mir_hsa-miR-624-5p 2.45 
25 mM glucose 478418_mir_hsa-miR-26b-5p 2.44 
25 mM glucose 478576_mir_hsa-let-7b-5p 2.42 
25 mM glucose 477971_mir_hsa-miR-2110 2.35 
25 mM glucose 478028_mir_hsa-miR-328-3p 2.30 
25 mM glucose 478347_mir_hsa-miR-33a-5p 2.28 
25 mM glucose 478342_mir_hsa-miR-766-3p 2.26 
25 mM glucose 478653_mir_hsa-miR-1248 2.21 
25 mM glucose 478058_mir_hsa-miR-362-3p 2.19 
25 mM glucose 478683_mir_hsa-miR-1282 2.19 
25 mM glucose 478043_mir_hsa-miR-342-3p 2.18 
25 mM glucose 478999_mir_hsa-miR-541-3p 2.17 
25 mM glucose 478432_mir_hsa-miR-483-5p 2.14 
25 mM glucose 479235_mir_hsa-miR-30e-5p 2.14 
25 mM glucose 478221_mir_hsa-let-7b-3p 2.13 
25 mM glucose 477835_mir_hsa-miR-487b-3p 2.12 
25 mM glucose 478135_mir_hsa-miR-494-3p 2.12 
25 mM glucose 479166_mir_hsa-miR-758-3p 2.10 
25 mM glucose 478641_mir_hsa-miR-1226-5p 2.09 
25 mM glucose 478199_mir_hsa-miR-7-2-3p 2.04 
25 mM glucose 478129_mir_hsa-miR-488-3p 2.01 
25 mM glucose 478074_mir_hsa-miR-375 2 
Up regulated 
Sample name Target name Fold change 
2.5 mM glucose 477895_mir_hsa-miR-1290 413.31 
2.5 mM glucose 478048_mir_hsa-miR-34a-5p 211.33 
2.5 mM glucose 478177_mir_hsa-miR-616-3p 108.29 
2.5 mM glucose 478270_mir_hsa-miR-27b-3p 41.39 
2.5 mM glucose 478826_mir_hsa-miR-323b-5p 28.29 
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2.5 mM glucose 479177_mir_hsa-miR-769-3p 26.98 
2.5 mM glucose 478753_mir_hsa-miR-200b-5p 22.61 
2.5 mM glucose 478620_mir_hsa-miR-101-5p 16.35 
2.5 mM glucose 477963_mir_hsa-miR-200b-3p 15.57 
2.5 mM glucose 478793_mir_hsa-miR-299-5p 14.57 
2.5 mM glucose 478065_mir_hsa-miR-365a-3p 11.67 
2.5 mM glucose 479115_mir_hsa-miR-633 11.41 
2.5 mM glucose 479041_mir_hsa-miR-556-3p 11.1 
2.5 mM glucose 479217_mir_hsa-miR-941 10.28 
2.5 mM glucose 478210_mir_hsa-miR-93-5p 9.5 
2.5 mM glucose 477879_mir_hsa-miR-124-3p 8.75 
2.5 mM glucose 478091_mir_hsa-miR-424-3p 7.59 
2.5 mM glucose 479374_mir_hsa-miR-548k 7.17 
2.5 mM glucose 477912_mir_hsa-miR-143-3p 6.66 
2.5 mM glucose 478749_mir_hsa-miR-198 6.25 
2.5 mM glucose 479297_mir_hsa-miR-513b-5p 5.78 
2.5 mM glucose 478165_mir_hsa-miR-576-5p 5.73 
2.5 mM glucose 478389_mir_hsa-miR-374b-5p 5.65 
2.5 mM glucose 479067_mir_hsa-miR-585-3p 5.64 
2.5 mM glucose 479469_mir_hsa-miR-625-5p 5.43 
2.5 mM glucose 477852_mir_hsa-miR-550a-5p 4.88 
2.5 mM glucose 478155_mir_hsa-miR-543 4.41 
2.5 mM glucose 479131_mir_hsa-miR-651-5p 4.37 
2.5 mM glucose 478238_mir_hsa-miR-374a-5p 3.87 
2.5 mM glucose 477902_mir_hsa-miR-136-3p 3.77 
2.5 mM glucose 478654_mir_hsa-miR-1249-3p 3.69 
2.5 mM glucose 478855_mir_hsa-miR-374a-3p 3.62 
2.5 mM glucose 479166_mir_hsa-miR-758-3p 3.58 
2.5 mM glucose 478191_mir_hsa-miR-655-3p 3.49 
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2.5 mM glucose 478741_mir_hsa-miR-192-3p 3.39 
2.5 mM glucose 478193_mir_hsa-miR-664a-3p 3.25 
2.5 mM glucose 478752_mir_hsa-miR-200a-5p 3.11 
2.5 mM glucose 477977_mir_hsa-miR-218-5p 3.1 
2.5 mM glucose 478335_mir_hsa-miR-496 3.1 
2.5 mM glucose 478253_mir_hsa-miR-103a-3p 3.08 
2.5 mM glucose 478134_mir_hsa-miR-493-3p 3.04 
2.5 mM glucose 478139_mir_hsa-miR-499a-5p 2.98 
2.5 mM glucose 477825_mir_hsa-miR-301b-3p 2.95 
2.5 mM glucose 479281_mir_hsa-let-7e-3p 2.95 
2.5 mM glucose 478602_mir_hsa-miR-23b-3p 2.85 
2.5 mM glucose 478040_mir_hsa-miR-339-5p 2.83 
2.5 mM glucose 478951_mir_hsa-miR-500a-3p 2.82 
2.5 mM glucose 479120_mir_hsa-miR-641 2.81 
2.5 mM glucose 478059_mir_hsa-miR-362-5p 2.81 
2.5 mM glucose 477904_mir_hsa-miR-137 2.76 
2.5 mM glucose 478384_mir_hsa-miR-27a-3p 2.73 
2.5 mM glucose 478318_mir_hsa-miR-212-3p 2.67 
2.5 mM glucose 478439_mir_hsa-let-7d-5p 2.61 
2.5 mM glucose 478494_mir_hsa-miR-10b-5p 2.58 
2.5 mM glucose 477934_mir_hsa-miR-181c-5p 2.55 
2.5 mM glucose 478027_mir_hsa-miR-326 2.43 
2.5 mM glucose 478582_mir_hsa-miR-135b-5p 2.41 
2.5 mM glucose 477976_mir_hsa-miR-216a-5p 2.4 
2.5 mM glucose 478132_mir_hsa-miR-491-5p 2.39 
2.5 mM glucose 479207_mir_hsa-miR-92b-5p 2.35 
2.5 mM glucose 479150_mir_hsa-miR-665 2.32 
2.5 mM glucose 478725_mir_hsa-miR-154-3p 2.31 
2.5 mM glucose 478490_mir_hsa-miR-200a-3p 2.16 
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2.5 mM glucose 477943_mir_hsa-miR-188-5p 2.13 
2.5 mM glucose 478130_mir_hsa-miR-489-3p 2.12 
2.5 mM glucose 478143_mir_hsa-miR-503-5p 2.08 
2.5 mM glucose 477853_mir_hsa-miR-323a-3p 2.08 
Down regulated 
Sample name Target name Fold change 
2.5 mM glucose 478591_mir_hsa-miR-302b-3p >500 
2.5 mM glucose 478719_mir_hsa-miR-148b-5p >500 
2.5 mM glucose 478732_mir_hsa-miR-185-3p 250 
2.5 mM glucose 478207_mir_hsa-miR-885-5p 200 
2.5 mM glucose 478687_mir_hsa-miR-1285-3p 200 
2.5 mM glucose 478175_mir_hsa-miR-615-3p 142.86 
2.5 mM glucose 479003_mir_hsa-miR-454-5p 83.33 
2.5 mM glucose 477921_mir_hsa-miR-152-3p 62.5 
2.5 mM glucose 478491_mir_hsa-miR-204-5p 38.46 
2.5 mM glucose 478163_mir_hsa-miR-574-3p 30.3 
2.5 mM glucose 478152_mir_hsa-miR-539-5p 18.18 
2.5 mM glucose 477929_mir_hsa-miR-15b-3p 14.71 
2.5 mM glucose 478068_mir_hsa-miR-369-5p 12.82 
2.5 mM glucose 477932_mir_hsa-miR-17-3p 12.35 
2.5 mM glucose 478307_mir_hsa-miR-136-5p 12.35 
2.5 mM glucose 478003_mir_hsa-miR-29b-2-5p 12.2 
2.5 mM glucose 478058_mir_hsa-miR-362-3p 12.2 
2.5 mM glucose 478501_mir_hsa-miR-141-3p 10.42 
2.5 mM glucose 478779_mir_hsa-miR-222-5p 9.52 
2.5 mM glucose 477980_mir_hsa-miR-219a-5p 9.26 
2.5 mM glucose 478012_mir_hsa-miR-31-3p 8.55 
2.5 mM glucose 477996_mir_hsa-miR-26b-3p 8.47 
2.5 mM glucose 478033_mir_hsa-miR-335-3p 7.14 
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2.5 mM glucose 477961_mir_hsa-miR-199a-3p 6.94 
2.5 mM glucose 478317_mir_hsa-miR-20a-3p 6.94 
2.5 mM glucose 477933_mir_hsa-miR-181c-3p 6.62 
2.5 mM glucose 478214_mir_hsa-miR-9-5p 6.29 
2.5 mM glucose 478032_mir_hsa-miR-331-5p 6.17 
2.5 mM glucose 477824_mir_hsa-miR-148b-3p 5.95 
2.5 mM glucose 479035_mir_hsa-miR-551b-5p 5.81 
2.5 mM glucose 479057_mir_hsa-miR-577 5.05 
2.5 mM glucose 478225_mir_hsa-miR-106a-5p 5 
2.5 mM glucose 478178_mir_hsa-miR-624-5p 4.93 
2.5 mM glucose 478179_mir_hsa-miR-625-3p 4.93 
2.5 mM glucose 478750_mir_hsa-miR-19a-5p 4.83 
2.5 mM glucose 478683_mir_hsa-miR-1282 4.74 
2.5 mM glucose 478153_mir_hsa-miR-542-3p 4.42 
2.5 mM glucose 479421_mir_hsa-miR-374b-3p 4.1 
2.5 mM glucose 478309_mir_hsa-miR-500a-5p 3.89 
2.5 mM glucose 478778_mir_hsa-miR-221-5p 3.86 
2.5 mM glucose 478060_mir_hsa-miR-363-3p 3.7 
2.5 mM glucose 479224_mir_hsa-miR-99a-3p 3.64 
2.5 mM glucose 478827_mir_hsa-miR-32-3p 3.45 
2.5 mM glucose 478156_mir_hsa-miR-544a 3.34 
2.5 mM glucose 478138_mir_hsa-miR-497-5p 3.31 
2.5 mM glucose 478578_mir_hsa-let-7f-5p 3.31 
2.5 mM glucose 477971_mir_hsa-miR-2110 3.27 
2.5 mM glucose 478513_mir_hsa-miR-146b-5p 3.24 
2.5 mM glucose 478028_mir_hsa-miR-328-3p 3.15 
2.5 mM glucose 478197_mir_hsa-miR-708-5p 3.07 
2.5 mM glucose 478422_mir_hsa-miR-486-3p 3.05 
2.5 mM glucose 479055_mir_hsa-miR-573 3.03 
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2.5 mM glucose 477931_mir_hsa-miR-16-2-3p 2.92 
2.5 mM glucose 478917_mir_hsa-miR-452-3p 2.89 
2.5 mM glucose 478859_mir_hsa-miR-376a-5p 2.85 
2.5 mM glucose 477928_mir_hsa-miR-15a-3p 2.82 
2.5 mM glucose 478329_mir_hsa-miR-454-3p 2.78 
2.5 mM glucose 478674_mir_hsa-miR-1271-5p 2.75 
2.5 mM glucose 477954_mir_hsa-miR-193a-5p 2.74 
2.5 mM glucose 479517_mir_hsa-miR-181d-5p 2.72 
2.5 mM glucose 478181_mir_hsa-miR-628-3p 2.65 
2.5 mM glucose 479229_mir_hsa-miR-29c-3p 2.65 
2.5 mM glucose 478690_mir_hsa-miR-1291 2.64 
2.5 mM glucose 478476_mir_hsa-miR-1260a 2.63 
2.5 mM glucose 478041_mir_hsa-miR-340-3p 2.6 
2.5 mM glucose 478784_mir_hsa-miR-24-1-5p 2.5 
2.5 mM glucose 477857_mir_hsa-miR-181a-5p 2.45 
2.5 mM glucose 478199_mir_hsa-miR-7-2-3p 2.43 
2.5 mM glucose 477890_mir_hsa-miR-1275 2.39 
2.5 mM glucose 478159_mir_hsa-miR-551b-3p 2.37 
2.5 mM glucose 478168_mir_hsa-miR-590-3p 2.33 
2.5 mM glucose 479526_mir_hsa-miR-411-3p 2.33 
2.5 mM glucose 478215_mir_hsa-miR-96-5p 2.32 
2.5 mM glucose 479228_mir_hsa-miR-19a-3p 2.28 
2.5 mM glucose 477962_mir_hsa-miR-19b-1-5p 2.23 
2.5 mM glucose 478362_mir_hsa-miR-548e-3p 2.2 
2.5 mM glucose 478231_mir_hsa-miR-199a-5p 2.18 
2.5 mM glucose 479003_mir_hsa-miR-545-5p 2.16 
2.5 mM glucose 478581_mir_hsa-miR-135a-5p 2.14 
2.5 mM glucose 478587_mir_hsa-miR-29a-3p 2.12 
2.5 mM glucose 477850_mir_hsa-let-7g-3p 2.11 
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2.5 mM glucose 478653_mir_hsa-miR-1248 2.11 
2.5 mM glucose 477899_mir_hsa-miR-130b-5p 2.11 
2.5 mM glucose 478043_mir_hsa-miR-342-3p 2.08 
2.5 mM glucose 478705_mir_hsa-miR-132-5p 2.07 
2.5 mM glucose 478131_mir_hsa-miR-490-3p 2.06 
2.5 mM glucose 477973_mir_hsa-miR-21-3p 2.02 
2.5 mM glucose 479235_mir_hsa-miR-30e-5p 2.02 
Up regulated 
Sample name Target name Fold change 
< 3% O2 478179_mir_hsa-miR-625-3p 66.28 
< 3% O2 478225_mir_hsa-miR-106a-5p 65.47 
< 3% O2 478210_mir_hsa-miR-93-5p 49.17 
< 3% O2 478788_mir_hsa-miR-26a-2-3p 46.85 
< 3% O2 478732_mir_hsa-miR-185-3p 26.11 
< 3% O2 479067_mir_hsa-miR-585-3p 24.27 
< 3% O2 477913_mir_hsa-miR-144-3p 20.59 
< 3% O2 478163_mir_hsa-miR-574-3p 16.69 
< 3% O2 478058_mir_hsa-miR-362-3p 15.41 
< 3% O2 477896_mir_hsa-miR-129-5p 15.18 
< 3% O2 478317_mir_hsa-miR-20a-3p 14.66 
< 3% O2 479177_mir_hsa-miR-769-3p 14.24 
< 3% O2 478494_mir_hsa-miR-10b-5p 12.27 
< 3% O2 478830_mir_hsa-miR-330-5p 11.83 
< 3% O2 478165_mir_hsa-miR-576-5p 11.74 
< 3% O2 479002_mir_hsa-miR-545-3p 10.88 
< 3% O2 478152_mir_hsa-miR-539-5p 10.64 
< 3% O2 478778_mir_hsa-miR-221-5p 10.21 
< 3% O2 478491_mir_hsa-miR-204-5p 9.01 
< 3% O2 478630_mir_hsa-miR-1197 7.77 
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< 3% O2 477902_mir_hsa-miR-136-3p 7.41 
< 3% O2 477922_mir_hsa-miR-153-3p 7.23 
< 3% O2 478439_mir_hsa-let-7d-5p 6.72 
< 3% O2 479448_mir_hsa-miR-30a-5p 6.12 
< 3% O2 478307_mir_hsa-miR-136-5p 6 
< 3% O2 477995_mir_hsa-miR-26a-5p 5.28 
< 3% O2 478743_mir_hsa-miR-194-3p 5.15 
< 3% O2 477885_mir_hsa-miR-125b-5p 5.05 
< 3% O2 479072_mir_hsa-miR-589-3p 5.04 
< 3% O2 479187_mir_hsa-miR-876-5p 5.02 
< 3% O2 480870_mir_hsa-miR-548d-5p 4.99 
< 3% O2 478641_mir_hsa-miR-1226-5p 4.97 
< 3% O2 478197_mir_hsa-miR-708-5p 4.89 
< 3% O2 477883_mir_hsa-miR-125a-3p 4.62 
< 3% O2 478041_mir_hsa-miR-340-3p 4.54 
< 3% O2 477951_mir_hsa-miR-191-3p 3.92 
< 3% O2 478191_mir_hsa-miR-655-3p 3.71 
< 3% O2 477855_mir_hsa-miR-122-5p 3.54 
< 3% O2 477928_mir_hsa-miR-15a-3p 3.49 
< 3% O2 479131_mir_hsa-miR-651-5p 3.48 
< 3% O2 477877_mir_hsa-miR-1233-3p 3.44 
< 3% O2 479228_mir_hsa-miR-19a-3p 3.41 
< 3% O2 478859_mir_hsa-miR-376a-5p 3.38 
< 3% O2 478136_mir_hsa-miR-495-3p 3.23 
< 3% O2 479121_mir_hsa-miR-642a-5p 3.22 
< 3% O2 477982_mir_hsa-miR-222-3p 3.21 
< 3% O2 478691_mir_hsa-miR-1292-5p 3.17 
< 3% O2 478644_mir_hsa-miR-1228-5p 3.15 
< 3% O2 479101_mir_hsa-miR-618 3.12 
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< 3% O2 478384_mir_hsa-miR-27a-3p 3.05 
< 3% O2 478157_mir_hsa-miR-548a-3p 3.03 
< 3% O2 477850_mir_hsa-let-7g-3p 3.02 
< 3% O2 478720_mir_hsa-miR-149-3p 3.01 
< 3% O2 477952_mir_hsa-miR-191-5p 2.93 
< 3% O2 478238_mir_hsa-miR-374a-5p 2.92 
< 3% O2 478490_mir_hsa-miR-200a-3p 2.92 
< 3% O2 478690_mir_hsa-miR-1291 2.83 
< 3% O2 478181_mir_hsa-miR-628-3p 2.81 
< 3% O2 478015_mir_hsa-miR-31-5p 2.77 
< 3% O2 478133_mir_hsa-miR-492 2.75 
< 3% O2 478084_mir_hsa-miR-409-3p 2.7 
< 3% O2 478138_mir_hsa-miR-497-5p 2.7 
< 3% O2 478126_mir_hsa-miR-485-5p 2.65 
< 3% O2 477987_mir_hsa-miR-22-5p 2.64 
< 3% O2 477980_mir_hsa-miR-219a-5p 2.56 
< 3% O2 479055_mir_hsa-miR-573 2.53 
< 3% O2 478230_mir_hsa-miR-196a-5p 2.51 
< 3% O2 479137_mir_hsa-miR-656-3p 2.49 
< 3% O2 478324_mir_hsa-miR-335-5p 2.47 
< 3% O2 478293_mir_cel-miR-39-3p 2.39 
< 3% O2 478389_mir_hsa-miR-374b-5p 2.38 
< 3% O2 478752_mir_hsa-miR-200a-5p 2.37 
< 3% O2 478306_mir_hsa-miR-193a-3p 2.32 
< 3% O2 479003_mir_hsa-miR-545-5p 2.29 
< 3% O2 478155_mir_hsa-miR-543 2.27 
< 3% O2 478368_mir_hsa-miR-654-5p 2.27 
< 3% O2 478088_mir_hsa-miR-421 2.26 
< 3% O2 478342_mir_hsa-miR-766-3p 2.24 
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< 3% O2 478215_mir_hsa-miR-96-5p 2.24 
< 3% O2 478023_mir_hsa-miR-324-3p 2.24 
< 3% O2 479517_mir_hsa-miR-181d-5p 2.23 
< 3% O2 478158_mir_hsa-miR-551a 2.23 
< 3% O2 477801_mir_hsa-let-7f-1-3p 2.22 
< 3% O2 477820_mir_hsa-miR-1-3p 2.2 
< 3% O2 478192_mir_hsa-miR-660-5p 2.16 
< 3% O2 478583_mir_hsa-miR-181b-5p 2.14 
< 3% O2 478388_mir_hsa-miR-30e-3p 2.13 
< 3% O2 479530_mir_hsa-miR-518d-5p 2.12 
< 3% O2 478586_mir_hsa-miR-20a-5p 2.12 
< 3% O2 477862_mir_hsa-let-7i-3p 2.11 
< 3% O2 477961_mir_hsa-miR-199a-3p 2.09 
< 3% O2 478205_mir_hsa-miR-874-3p 2.09 
< 3% O2 477956_mir_hsa-miR-194-5p 2.04 
< 3% O2 479000_mir_hsa-miR-541-5p 2.03 
< 3% O2 479405_mir_hsa-miR-181a-3p 2.01 
< 3% O2 478128_mir_hsa-miR-486-5p 2.01 
< 3% O2 478193_mir_hsa-miR-664a-3p 2 
Down regulated 
Sample name Target name Fold change 
< 3% O2 478025_mir_hsa-miR-325 >500 
< 3% O2  478237_mir_hsa-miR-302d-3p  >500 
< 3% O2 478860_mir_hsa-miR-376b-3p >500 
< 3% O2 478995_mir_hsa-miR-525-3p >500 
< 3% O2 478207_mir_hsa-miR-885-5p >500 
< 3% O2 479003_mir_hsa-miR-454-5p 76.92 
< 3% O2 477921_mir_hsa-miR-152-3p 66.67 
< 3% O2 478307_mir_hsa-miR-136-5p 24.39 
50 
 
< 3% O2 478214_mir_hsa-miR-9-5p 15.15 
< 3% O2 477879_mir_hsa-miR-124-3p 14.49 
< 3% O2 478793_mir_hsa-miR-299-5p 14.29 
< 3% O2 478270_mir_hsa-miR-27b-3p 11.76 
< 3% O2 479053_mir_hsa-miR-570-3p 10.75 
< 3% O2 477929_mir_hsa-miR-15b-3p 10.53 
< 3% O2 478339_mir_hsa-miR-597-5p 9.62 
< 3% O2 477963_mir_hsa-miR-200b-3p 9.52 
< 3% O2 477973_mir_hsa-miR-21-3p 9.52 
< 3% O2 479073_mir_hsa-miR-589-5p 8.93 
< 3% O2 478240_mir_hsa-miR-376a-3p 8.2 
< 3% O2 477959_mir_hsa-miR-197-3p 7.63 
< 3% O2 478177_mir_hsa-miR-616-3p 6.9 
< 3% O2 478544_mir_hsa-miR-129-2-3p 6.37 
< 3% O2 478687_mir_hsa-miR-1285-3p 6.1 
< 3% O2 478273_mir_hsa-miR-30a-3p 4.65 
< 3% O2 478035_mir_hsa-miR-337-3p 4.24 
< 3% O2 479022_mir_hsa-miR-548j-5p 3.82 
< 3% O2 478620_mir_hsa-miR-101-5p 3.77 
< 3% O2 478130_mir_hsa-miR-489-3p 3.66 
< 3% O2 478139_mir_hsa-miR-499a-5p 3.5 
< 3% O2 478725_mir_hsa-miR-154-3p 3.48 
< 3% O2 479035_mir_hsa-miR-551b-5p 3.48 
< 3% O2 478479_mir_hsa-miR-33b-5p 3.46 
< 3% O2 478087_mir_hsa-miR-412-3p 3.45 
< 3% O2 477899_mir_hsa-miR-130b-5p 3.36 
< 3% O2 478581_mir_hsa-miR-135a-5p 3.32 
< 3% O2 477895_mir_hsa-miR-1290 3.21 
< 3% O2 479207_mir_hsa-miR-92b-5p 3.21 
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< 3% O2 477825_mir_hsa-miR-301b-3p 3.17 
< 3% O2 478076_mir_hsa-miR-378a-5p 3.03 
< 3% O2 478159_mir_hsa-miR-551b-3p 2.99 
< 3% O2 479526_mir_hsa-miR-411-3p 2.99 
< 3% O2 477954_mir_hsa-miR-193a-5p 2.87 
< 3% O2 478369_mir_hsa-miR-29b-3p 2.78 
< 3% O2 478594_mir_hsa-miR-320a 2.75 
< 3% O2 478718_mir_hsa-miR-148a-5p 2.66 
< 3% O2 477944_mir_hsa-miR-18a-3p 2.6 
< 3% O2 478168_mir_hsa-miR-590-3p 2.53 
< 3% O2 478203_mir_hsa-miR-769-5p 2.51 
< 3% O2 478683_mir_hsa-miR-1282 2.49 
< 3% O2 478113_mir_hsa-miR-455-5p 2.46 
< 3% O2 478914_mir_hsa-miR-450b-5p 2.42 
< 3% O2 478026_mir_hsa-miR-32-5p 2.4 
< 3% O2 477937_mir_hsa-miR-183-5p 2.35 
< 3% O2 479212_mir_hsa-miR-937-3p 2.29 
< 3% O2 477991_mir_hsa-miR-23b-5p 2.28 
< 3% O2 477890_mir_hsa-miR-1275 2.22 
< 3% O2 478262_mir_hsa-miR-192-5p 2.22 
< 3% O2 478033_mir_hsa-miR-335-3p 2.14 
< 3% O2 478134_mir_hsa-miR-493-3p 2.12 
< 3% O2 479178_mir_hsa-miR-770-5p 2.11 
< 3% O2 478060_mir_hsa-miR-363-3p 2.1 
< 3% O2 477866_mir_hsa-miR-106b-3p 2.09 
< 3% O2 478326_mir_hsa-miR-370-3p 2.09 
< 3% O2 477816_mir_hsa-miR-381-3p 2.05 
Up regulated 
Sample name Target name Fold change 
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0.5 mM Palmitic Acid 478513_mir_hsa-miR-146b-5p 443.64 
0.5 mM Palmitic Acid 478913_mir_hsa-miR-450b-3p 364.07 
0.5 mM Palmitic Acid 477936_mir_hsa-miR-183-3p 82.6 
0.5 mM Palmitic Acid 478273_mir_hsa-miR-30a-3p 65.08 
0.5 mM Palmitic Acid 478384_mir_hsa-miR-27a-3p 52.77 
0.5 mM Palmitic Acid 478065_mir_hsa-miR-365a-3p 47.34 
0.5 mM Palmitic Acid 478210_mir_hsa-miR-93-5p 42.43 
0.5 mM Palmitic Acid 478785_mir_hsa-miR-24-2-5p 35.22 
0.5 mM Palmitic Acid 478432_mir_hsa-miR-483-5p 17.63 
0.5 mM Palmitic Acid 478179_mir_hsa-miR-625-3p 14.78 
0.5 mM Palmitic Acid 478293_mir_cel-miR-39-3p 14.23 
0.5 mM Palmitic Acid 478793_mir_hsa-miR-299-5p 10.98 
0.5 mM Palmitic Acid 479115_mir_hsa-miR-633 9.19 
0.5 mM Palmitic Acid 478200_mir_hsa-miR-744-5p 8.52 
0.5 mM Palmitic Acid 479374_mir_hsa-miR-548k 7.6 
0.5 mM Palmitic Acid 479041_mir_hsa-miR-556-3p 7.36 
0.5 mM Palmitic Acid 478165_mir_hsa-miR-576-5p 7.05 
0.5 mM Palmitic Acid 479281_mir_hsa-let-7e-3p 7.01 
0.5 mM Palmitic Acid 477933_mir_hsa-miR-181c-3p 6.81 
0.5 mM Palmitic Acid 477879_mir_hsa-miR-124-3p 6.67 
0.5 mM Palmitic Acid 478183_mir_hsa-miR-629-5p 6.56 
0.5 mM Palmitic Acid 478155_mir_hsa-miR-543 6.43 
0.5 mM Palmitic Acid 478145_mir_hsa-miR-505-3p 6.16 
0.5 mM Palmitic Acid 478164_mir_hsa-miR-576-3p 5.84 
0.5 mM Palmitic Acid 478191_mir_hsa-miR-655-3p 5.56 
0.5 mM Palmitic Acid 478126_mir_hsa-miR-485-5p 5.46 
0.5 mM Palmitic Acid 477863_mir_hsa-miR-101-3p 5.27 
0.5 mM Palmitic Acid 478594_mir_hsa-miR-320a 5.11 
0.5 mM Palmitic Acid 478790_mir_hsa-miR-296-3p 4.72 
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0.5 mM Palmitic Acid 477976_mir_hsa-miR-216a-5p 4.58 
0.5 mM Palmitic Acid 478602_mir_hsa-miR-23b-3p 4.52 
0.5 mM Palmitic Acid 477851_mir_hsa-miR-130a-3p 4.34 
0.5 mM Palmitic Acid 477918_mir_hsa-miR-150-5p 4.32 
0.5 mM Palmitic Acid 478029_mir_hsa-miR-329-3p 4.04 
0.5 mM Palmitic Acid 479176_mir_hsa-miR-767-5p 4.01 
0.5 mM Palmitic Acid 478544_mir_hsa-miR-129-2-3p 3.79 
0.5 mM Palmitic Acid 477963_mir_hsa-miR-200b-3p 3.7 
0.5 mM Palmitic Acid 478476_mir_hsa-miR-1260a 3.62 
0.5 mM Palmitic Acid 479059_mir_hsa-miR-579-3p 3.61 
0.5 mM Palmitic Acid 478579_mir_hsa-let-7e-5p 3.5 
0.5 mM Palmitic Acid 477952_mir_hsa-miR-191-5p 3.3 
0.5 mM Palmitic Acid 477826_mir_hsa-miR-487a-3p 3.17 
0.5 mM Palmitic Acid 477942_mir_hsa-miR-188-3p 2.98 
0.5 mM Palmitic Acid 479121_mir_hsa-miR-642a-5p 2.96 
0.5 mM Palmitic Acid 478580_mir_hsa-let-7g-5p 2.92 
0.5 mM Palmitic Acid 477835_mir_hsa-miR-487b-3p 2.87 
0.5 mM Palmitic Acid 478619_mir_hsa-miR-100-3p 2.84 
0.5 mM Palmitic Acid 477943_mir_hsa-miR-188-5p 2.83 
0.5 mM Palmitic Acid 478362_mir_hsa-miR-548e-3p 2.81 
0.5 mM Palmitic Acid 478327_mir_hsa-miR-423-3p 2.78 
0.5 mM Palmitic Acid 478023_mir_hsa-miR-324-3p 2.74 
0.5 mM Palmitic Acid 478389_mir_hsa-miR-374b-5p 2.73 
0.5 mM Palmitic Acid 478101_mir_hsa-miR-432-5p 2.67 
0.5 mM Palmitic Acid 478578_mir_hsa-let-7f-5p 2.64 
0.5 mM Palmitic Acid 478576_mir_hsa-let-7b-5p 2.62 
0.5 mM Palmitic Acid 478720_mir_hsa-miR-149-3p 2.61 
0.5 mM Palmitic Acid 478575_mir_hsa-let-7a-5p 2.58 
0.5 mM Palmitic Acid 478203_mir_hsa-miR-769-5p 2.42 
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0.5 mM Palmitic Acid 479131_mir_hsa-miR-651-5p 2.4 
0.5 mM Palmitic Acid 478626_mir_hsa-miR-1179 2.38 
0.5 mM Palmitic Acid 477957_mir_hsa-miR-195-5p 2.29 
0.5 mM Palmitic Acid 478314_mir_hsa-miR-193b-3p 2.27 
0.5 mM Palmitic Acid 478375_mir_hsa-let-7i-5p 2.22 
0.5 mM Palmitic Acid 478494_mir_hsa-miR-10b-5p 2.15 
0.5 mM Palmitic Acid 478349_mir_hsa-miR-378a-3p 2.14 
0.5 mM Palmitic Acid 478318_mir_hsa-miR-212-3p 2.1 
0.5 mM Palmitic Acid 477994_mir_hsa-miR-25-3p 2.09 
0.5 mM Palmitic Acid 478789_mir_hsa-miR-27b-5p 2.09 
0.5 mM Palmitic Acid 477921_mir_hsa-miR-152-3p 2.07 
0.5 mM Palmitic Acid 477904_mir_hsa-miR-137 2.04 
0.5 mM Palmitic Acid 478028_mir_hsa-miR-328-3p 2.02 
0.5 mM Palmitic Acid 477992_mir_hsa-miR-24-3p 2.02 
0.5 mM Palmitic Acid 478030_mir_hsa-miR-330-3p 2.01 
0.5 mM Palmitic Acid 478078_mir_hsa-miR-382-5p 2.01 
0.5 mM Palmitic Acid 478691_mir_hsa-miR-1292-5p 2 
Down regulated 
Sample name Target name Fold change 
0.5 mM Palmitic Acid 477962_mir_hsa-miR-19b-1-5p >500 
0.5 mM Palmitic Acid 478168_mir_hsa-miR-454-5p 142.86 
0.5 mM Palmitic Acid 477913_mir_hsa-miR-144-3p 90.91 
0.5 mM Palmitic Acid 478917_mir_hsa-miR-452-3p 83.33 
0.5 mM Palmitic Acid 478270_mir_hsa-miR-27b-3p 30.3 
0.5 mM Palmitic Acid 478732_mir_hsa-miR-185-3p 27.03 
0.5 mM Palmitic Acid 478831_mir_hsa-miR-33a-3p 22.22 
0.5 mM Palmitic Acid 478307_mir_hsa-miR-136-5p 15.38 
0.5 mM Palmitic Acid 478329_mir_hsa-miR-454-3p 11.36 
0.5 mM Palmitic Acid 478660_mir_hsa-miR-1254 9.8 
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0.5 mM Palmitic Acid 478207_mir_hsa-miR-885-5p 9.35 
0.5 mM Palmitic Acid 478240_mir_hsa-miR-376a-3p 9.35 
0.5 mM Palmitic Acid 478138_mir_hsa-miR-497-5p 8.7 
0.5 mM Palmitic Acid 479166_mir_hsa-miR-758-3p 8.62 
0.5 mM Palmitic Acid 479000_mir_hsa-miR-541-5p 7.52 
0.5 mM Palmitic Acid 478158_mir_hsa-miR-551a 7.14 
0.5 mM Palmitic Acid 479055_mir_hsa-miR-573 7.14 
0.5 mM Palmitic Acid 477931_mir_hsa-miR-16-2-3p 6.9 
0.5 mM Palmitic Acid 478264_mir_hsa-miR-19b-3p 6.8 
0.5 mM Palmitic Acid 478754_mir_hsa-miR-200c-5p 6.58 
0.5 mM Palmitic Acid 479134_mir_hsa-miR-653-5p 6.54 
0.5 mM Palmitic Acid 477961_mir_hsa-miR-199a-3p 5.62 
0.5 mM Palmitic Acid 479002_mir_hsa-miR-545-3p 5.52 
0.5 mM Palmitic Acid 478113_mir_hsa-miR-455-5p 5.41 
0.5 mM Palmitic Acid 479469_mir_hsa-miR-625-5p 5.38 
0.5 mM Palmitic Acid 479205_mir_hsa-miR-92a-1-5p 5.26 
0.5 mM Palmitic Acid 478163_mir_hsa-miR-574-3p 5.24 
0.5 mM Palmitic Acid 478197_mir_hsa-miR-708-5p 5.24 
0.5 mM Palmitic Acid 478705_mir_hsa-miR-132-5p 5.13 
0.5 mM Palmitic Acid 478178_mir_hsa-miR-624-5p 5.05 
0.5 mM Palmitic Acid 478369_mir_hsa-miR-29b-3p 4.98 
0.5 mM Palmitic Acid 478784_mir_hsa-miR-24-1-5p 4.95 
0.5 mM Palmitic Acid 477932_mir_hsa-miR-17-3p 4.83 
0.5 mM Palmitic Acid 478068_mir_hsa-miR-369-5p 4.69 
0.5 mM Palmitic Acid 478181_mir_hsa-miR-628-3p 4.59 
0.5 mM Palmitic Acid 478193_mir_hsa-miR-664a-3p 4.57 
0.5 mM Palmitic Acid 479530_mir_hsa-miR-518d-5p 4.52 
0.5 mM Palmitic Acid 478341_mir_hsa-miR-7-5p 4.37 
0.5 mM Palmitic Acid 478804_mir_hsa-miR-30b-3p 4.29 
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0.5 mM Palmitic Acid 477959_mir_hsa-miR-197-3p 3.82 
0.5 mM Palmitic Acid 479003_mir_hsa-miR-545-5p 3.75 
0.5 mM Palmitic Acid 478199_mir_hsa-miR-7-2-3p 3.57 
0.5 mM Palmitic Acid 478216_mir_hsa-miR-99b-3p 3.57 
0.5 mM Palmitic Acid 478003_mir_hsa-miR-29b-2-5p 3.53 
0.5 mM Palmitic Acid 478015_mir_hsa-miR-31-5p 3.37 
0.5 mM Palmitic Acid 478674_mir_hsa-miR-1271-5p 3.34 
0.5 mM Palmitic Acid 479187_mir_hsa-miR-876-5p 3.33 
0.5 mM Palmitic Acid 477973_mir_hsa-miR-21-3p 3.28 
0.5 mM Palmitic Acid 477823_mir_hsa-miR-92b-3p 3.18 
0.5 mM Palmitic Acid 478238_mir_hsa-miR-374a-5p 3.04 
0.5 mM Palmitic Acid 477804_mir_hsa-miR-20b-5p 3.03 
0.5 mM Palmitic Acid 478587_mir_hsa-miR-29a-3p 2.99 
0.5 mM Palmitic Acid 478792_mir_hsa-miR-299-3p 2.97 
0.5 mM Palmitic Acid 478826_mir_hsa-miR-323b-5p 2.95 
0.5 mM Palmitic Acid 478622_mir_hsa-miR-105-3p 2.92 
0.5 mM Palmitic Acid 479229_mir_hsa-miR-29c-3p 2.88 
0.5 mM Palmitic Acid 477939_mir_hsa-miR-185-5p 2.87 
0.5 mM Palmitic Acid 478630_mir_hsa-miR-1197 2.85 
0.5 mM Palmitic Acid 479150_mir_hsa-miR-665 2.85 
0.5 mM Palmitic Acid 478491_mir_hsa-miR-204-5p 2.83 
0.5 mM Palmitic Acid 477887_mir_hsa-miR-126-3p 2.8 
0.5 mM Palmitic Acid 477982_mir_hsa-miR-222-3p 2.77 
0.5 mM Palmitic Acid 478196_mir_hsa-miR-675-5p 2.65 
0.5 mM Palmitic Acid 477901_mir_hsa-miR-134-5p 2.62 
0.5 mM Palmitic Acid 478752_mir_hsa-miR-200a-5p 2.61 
0.5 mM Palmitic Acid 479532_mir_hsa-miR-518f-5p 2.6 
0.5 mM Palmitic Acid 478209_mir_hsa-miR-93-3p 2.6 
0.5 mM Palmitic Acid 478055_mir_hsa-miR-361-3p 2.57 
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0.5 mM Palmitic Acid 479451_mir_hsa-miR-1296-5p 2.57 
0.5 mM Palmitic Acid 479405_mir_hsa-miR-181a-3p 2.56 
0.5 mM Palmitic Acid 477922_mir_hsa-miR-153-3p 2.55 
0.5 mM Palmitic Acid 477866_mir_hsa-miR-106b-3p 2.53 
0.5 mM Palmitic Acid 477885_mir_hsa-miR-125b-5p 2.53 
0.5 mM Palmitic Acid 478159_mir_hsa-miR-551b-3p 2.53 
0.5 mM Palmitic Acid 480871_mir_hsa-miR-133b 2.5 
0.5 mM Palmitic Acid 478221_mir_hsa-let-7b-3p 2.49 
0.5 mM Palmitic Acid 477951_mir_hsa-miR-191-3p 2.48 
0.5 mM Palmitic Acid 480872_mir_hsa-miR-548am-5p 2.48 
0.5 mM Palmitic Acid 478033_mir_hsa-miR-335-3p 2.46 
0.5 mM Palmitic Acid 478192_mir_hsa-miR-660-5p 2.39 
0.5 mM Palmitic Acid 478052_mir_hsa-miR-34c-5p 2.34 
0.5 mM Palmitic Acid 478368_mir_hsa-miR-654-5p 2.33 
0.5 mM Palmitic Acid 478060_mir_hsa-miR-363-3p 2.29 
0.5 mM Palmitic Acid 479217_mir_hsa-miR-941 2.28 
0.5 mM Palmitic Acid 478342_mir_hsa-miR-766-3p 2.27 
0.5 mM Palmitic Acid 478253_mir_hsa-miR-103a-3p 2.24 
0.5 mM Palmitic Acid 478048_mir_hsa-miR-34a-5p 2.22 
0.5 mM Palmitic Acid 477824_mir_hsa-miR-148b-3p 2.2 
0.5 mM Palmitic Acid 478106_mir_hsa-miR-450a-5p 2.2 
0.5 mM Palmitic Acid 478175_mir_hsa-miR-615-3p 2.19 
0.5 mM Palmitic Acid 478412_mir_hsa-miR-106b-5p 2.16 
0.5 mM Palmitic Acid 477899_mir_hsa-miR-130b-5p 2.15 
0.5 mM Palmitic Acid 478185_mir_hsa-miR-636 2.09 
0.5 mM Palmitic Acid 479135_mir_hsa-miR-654-3p 2.07 
0.5 mM Palmitic Acid 478067_mir_hsa-miR-369-3p 2.06 




Sample name Target name Fold change 
cytokine treatment 479530_mir_hsa-miR-518d-5p >500 
cytokine treatment 477933_mir_hsa-miR-181c-3p 215.01 
cytokine treatment 477936_mir_hsa-miR-183-3p 73.72 
cytokine treatment 478793_mir_hsa-miR-299-5p 41.94 
cytokine treatment 478183_mir_hsa-miR-629-5p 23.86 
cytokine treatment 478691_mir_hsa-miR-1292-5p 21.08 
cytokine treatment 477921_mir_hsa-miR-152-3p 19.5 
cytokine treatment 478318_mir_hsa-miR-212-3p 18.71 
cytokine treatment 478432_mir_hsa-miR-483-5p 18.4 
cytokine treatment 478913_mir_hsa-miR-450b-3p 13.88 
cytokine treatment 479067_mir_hsa-miR-585-3p 13.03 
cytokine treatment 478683_mir_hsa-miR-1282 12.96 
cytokine treatment 477929_mir_hsa-miR-15b-3p 11.4 
cytokine treatment 479057_mir_hsa-miR-577 10.78 
cytokine treatment 479115_mir_hsa-miR-633 9.67 
cytokine treatment 478513_mir_hsa-miR-146b-5p 9.53 
cytokine treatment 478153_mir_hsa-miR-542-3p 8.76 
cytokine treatment 478790_mir_hsa-miR-296-3p 7.61 
cytokine treatment 479131_mir_hsa-miR-651-5p 6.97 
cytokine treatment 478753_mir_hsa-miR-200b-5p 6.74 
cytokine treatment 479421_mir_hsa-miR-374b-3p 6.49 
cytokine treatment 478587_mir_hsa-miR-29a-3p 6.13 
cytokine treatment 478065_mir_hsa-miR-365a-3p 5.56 
cytokine treatment 478590_mir_hsa-miR-98-5p 5.44 
cytokine treatment 478389_mir_hsa-miR-374b-5p 4.79 
cytokine treatment 479374_mir_hsa-miR-548k 4.67 
cytokine treatment 478041_mir_hsa-miR-340-3p 4.19 
cytokine treatment 477896_mir_hsa-miR-129-5p 4.02 
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cytokine treatment 479134_mir_hsa-miR-653-5p 3.61 
cytokine treatment 479212_mir_hsa-miR-937-3p 3.54 
cytokine treatment 478191_mir_hsa-miR-655-3p 3.47 
cytokine treatment 477963_mir_hsa-miR-200b-3p 3.45 
cytokine treatment 477976_mir_hsa-miR-216a-5p 3.29 
cytokine treatment 478214_mir_hsa-miR-9-5p 3.28 
cytokine treatment 477863_mir_hsa-miR-101-3p 3.2 
cytokine treatment 478145_mir_hsa-miR-505-3p 3.11 
cytokine treatment 477804_mir_hsa-miR-20b-5p 3.04 
cytokine treatment 477931_mir_hsa-miR-16-2-3p 3.04 
cytokine treatment 479176_mir_hsa-miR-767-5p 2.89 
cytokine treatment 477980_mir_hsa-miR-219a-5p 2.8 
cytokine treatment 477895_mir_hsa-miR-1290 2.8 
cytokine treatment 479207_mir_hsa-miR-92b-5p 2.74 
cytokine treatment 478038_mir_hsa-miR-338-5p 2.63 
cytokine treatment 477918_mir_hsa-miR-150-5p 2.5 
cytokine treatment 478752_mir_hsa-miR-200a-5p 2.5 
cytokine treatment 478602_mir_hsa-miR-23b-3p 2.44 
cytokine treatment 478494_mir_hsa-miR-10b-5p 2.43 
cytokine treatment 478544_mir_hsa-miR-129-2-3p 2.24 
cytokine treatment 478325_mir_hsa-miR-339-3p 2.24 
cytokine treatment 478773_mir_hsa-miR-217 2.16 
cytokine treatment 478743_mir_hsa-miR-194-3p 2.12 
cytokine treatment 478155_mir_hsa-miR-543 2.05 
cytokine treatment 477952_mir_hsa-miR-191-5p 2.02 
Down regulated 
Sample name Target name Fold change 
cytokine treatment 479064_mir_hsa-miR-582-3p 333.33 
cytokine treatment 478914_mir_hsa-miR-450b-5p 200 
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cytokine treatment 477913_mir_hsa-miR-144-3p 166.67 
cytokine treatment 478177_mir_hsa-miR-616-3p 142.86 
cytokine treatment 478307_mir_hsa-miR-136-5p 66.67 
cytokine treatment 478827_mir_hsa-miR-32-3p 62.5 
cytokine treatment 478207_mir_hsa-miR-885-5p 55.56 
cytokine treatment 479059_mir_hsa-miR-579-3p 35.71 
cytokine treatment 479041_mir_hsa-miR-556-3p 32.26 
cytokine treatment 478131_mir_hsa-miR-490-3p 27.78 
cytokine treatment 478270_mir_hsa-miR-27b-3p 22.73 
cytokine treatment 478139_mir_hsa-miR-499a-5p 21.28 
cytokine treatment 477879_mir_hsa-miR-124-3p 16.67 
cytokine treatment 478210_mir_hsa-miR-93-5p 14.29 
cytokine treatment 478060_mir_hsa-miR-363-3p 12.35 
cytokine treatment 478329_mir_hsa-miR-454-3p 11.49 
cytokine treatment 479003_mir_hsa-miR-545-5p 11.49 
cytokine treatment 478831_mir_hsa-miR-33a-3p 10.75 
cytokine treatment 478306_mir_hsa-miR-193a-3p 10.1 
cytokine treatment 478152_mir_hsa-miR-539-5p 9.9 
cytokine treatment 478491_mir_hsa-miR-204-5p 9.01 
cytokine treatment 479405_mir_hsa-miR-181a-3p 8.93 
cytokine treatment 477962_mir_hsa-miR-19b-1-5p 8.2 
cytokine treatment 478199_mir_hsa-miR-7-2-3p 7.87 
cytokine treatment 478015_mir_hsa-miR-31-5p 6.76 
cytokine treatment 478532_mir_hsa-miR-23a-3p 6.37 
cytokine treatment 478025_mir_hsa-miR-325 5.99 
cytokine treatment 477937_mir_hsa-miR-183-5p 5.95 
cytokine treatment 479047_mir_hsa-miR-562 5.92 
cytokine treatment 478179_mir_hsa-miR-625-3p 5.62 
cytokine treatment 477853_mir_hsa-miR-323a-3p 5.41 
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cytokine treatment 477888_mir_hsa-miR-126-5p 5.15 
cytokine treatment 478804_mir_hsa-miR-30b-3p 5.1 
cytokine treatment 478113_mir_hsa-miR-455-5p 5.05 
cytokine treatment 478012_mir_hsa-miR-31-3p 5.05 
cytokine treatment 478349_mir_hsa-miR-378a-3p 5 
cytokine treatment 478888_mir_hsa-miR-431-3p 4.81 
cytokine treatment 478826_mir_hsa-miR-323b-5p 4.74 
cytokine treatment 478586_mir_hsa-miR-20a-5p 4.69 
cytokine treatment 478002_mir_hsa-miR-29a-5p 4.65 
cytokine treatment 478657_mir_hsa-miR-1251-5p 4.61 
cytokine treatment 479032_mir_hsa-miR-550a-3p 4.46 
cytokine treatment 477814_mir_hsa-miR-148a-3p 4.42 
cytokine treatment 478209_mir_hsa-miR-93-3p 4.2 
cytokine treatment 477959_mir_hsa-miR-197-3p 4.17 
cytokine treatment 480871_mir_hsa-miR-133b 4.07 
cytokine treatment 478102_mir_hsa-miR-433-3p 3.91 
cytokine treatment 477909_mir_hsa-miR-140-5p 3.89 
cytokine treatment 477991_mir_hsa-miR-23b-5p 3.89 
cytokine treatment 477900_mir_hsa-miR-132-3p 3.88 
cytokine treatment 478240_mir_hsa-miR-376a-3p 3.73 
cytokine treatment 478238_mir_hsa-miR-374a-5p 3.69 
cytokine treatment 479150_mir_hsa-miR-665 3.68 
cytokine treatment 477901_mir_hsa-miR-134-5p 3.57 
cytokine treatment 478033_mir_hsa-miR-335-3p 3.57 
cytokine treatment 479024_mir_hsa-miR-548n 3.32 
cytokine treatment 478134_mir_hsa-miR-493-3p 3.29 
cytokine treatment 478068_mir_hsa-miR-369-5p 3.27 
cytokine treatment 477862_mir_hsa-let-7i-3p 3.19 
cytokine treatment 477971_mir_hsa-miR-2110 3.17 
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cytokine treatment 477917_mir_hsa-miR-149-5p 3.12 
cytokine treatment 477982_mir_hsa-miR-222-3p 3.12 
cytokine treatment 478143_mir_hsa-miR-503-5p 3.09 
cytokine treatment 477843_mir_hsa-let-7f-2-3p 2.99 
cytokine treatment 477824_mir_hsa-miR-148b-3p 2.98 
cytokine treatment 477816_mir_hsa-miR-381-3p 2.96 
cytokine treatment 477887_mir_hsa-miR-126-3p 2.88 
cytokine treatment 477939_mir_hsa-miR-185-5p 2.79 
cytokine treatment 478511_mir_hsa-miR-133a-3p 2.79 
cytokine treatment 477849_mir_hsa-miR-429 2.79 
cytokine treatment 477922_mir_hsa-miR-153-3p 2.75 
cytokine treatment 477902_mir_hsa-miR-136-3p 2.67 
cytokine treatment 477961_mir_hsa-miR-199a-3p 2.65 
cytokine treatment 479451_mir_hsa-miR-1296-5p 2.65 
cytokine treatment 479517_mir_hsa-miR-181d-5p 2.65 
cytokine treatment 478164_mir_hsa-miR-576-3p 2.62 
cytokine treatment 477944_mir_hsa-miR-18a-3p 2.6 
cytokine treatment 478476_mir_hsa-miR-1260a 2.59 
cytokine treatment 478551_mir_hsa-miR-18a-5p 2.56 
cytokine treatment 477857_mir_hsa-miR-181a-5p 2.46 
cytokine treatment 477912_mir_hsa-miR-143-3p 2.44 
cytokine treatment 477811_mir_hsa-miR-151b 2.42 
cytokine treatment 478158_mir_hsa-miR-551a 2.41 
cytokine treatment 477925_mir_hsa-miR-154-5p 2.38 
cytokine treatment 479217_mir_hsa-miR-941 2.38 
cytokine treatment 478005_mir_hsa-miR-29c-5p 2.38 
cytokine treatment 478128_mir_hsa-miR-486-5p 2.37 
cytokine treatment 478855_mir_hsa-miR-374a-3p 2.37 
cytokine treatment 479229_mir_hsa-miR-29c-3p 2.36 
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cytokine treatment 477866_mir_hsa-miR-106b-3p 2.34 
cytokine treatment 478348_mir_hsa-miR-502-3p 2.29 
cytokine treatment 478999_mir_hsa-miR-541-3p 2.28 
cytokine treatment 478654_mir_hsa-miR-1249-3p 2.26 
cytokine treatment 479166_mir_hsa-miR-758-3p 2.25 
cytokine treatment 479165_mir_hsa-miR-744-3p 2.23 
cytokine treatment 478043_mir_hsa-miR-342-3p 2.23 
cytokine treatment 478172_mir_hsa-miR-598-3p 2.21 
cytokine treatment 477956_mir_hsa-miR-194-5p 2.16 
cytokine treatment 478193_mir_hsa-miR-664a-3p 2.16 
cytokine treatment 478253_mir_hsa-miR-103a-3p 2.14 
cytokine treatment 478125_mir_hsa-miR-485-3p 2.13 
cytokine treatment 477987_mir_hsa-miR-22-5p 2.12 
cytokine treatment 479281_mir_hsa-let-7e-3p 2.12 
cytokine treatment 478459_mir_hsa-miR-376c-3p 2.1 
cytokine treatment 478313_mir_hsa-miR-15b-5p 2.07 
cytokine treatment 478040_mir_hsa-miR-339-5p 2.06 
cytokine treatment 477941_mir_hsa-miR-187-3p 2.05 
cytokine treatment 478026_mir_hsa-miR-32-5p 2.05 
cytokine treatment 478027_mir_hsa-miR-326 2.04 
cytokine treatment 478090_mir_hsa-miR-423-5p 2.04 
cytokine treatment 478362_mir_hsa-miR-548e-3p 2.04 
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Supplemental table S2. Selected 10 most dysregulated microRNA assay IDs 642 
 643 
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Supplemental table S3. Assay IDs for predicted mRNA targets. 647 
 648 
Gene Assay ID RefSeq 
PPIA Hs.PT.58v.38887593.g NM_021130 
HPRT1 Hs.PT.58.2145446 NM_000194 
IDH3B Hs.PT.19660618  NM_174855 
MOB1A Hs.PT.58.1530191 NM_018221 
PDK1 Hs.PT.58.19794808 NM_002610 
SOD1 Hs.PT.58.20593019 NM_000454 
SP1 Hs.PT.58.19745651 NM_138473 
KMT2C Hs.PT.19586130 NM_170606 
DLG2 Hs.PT.58.28262784 NM_001142702 
BCL2L1 Hs.PT.56a.39595693.g NM_138578 
MAPK1 Hs.PT.58.39782850 NM_138957 
SERPINE1 Hs.PT.58.3938488.g NM_000602 
TEAD1 Hs.PT.58.22785339 NM_021961 
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